Macrocyclic EGFR (epidermal growth factor receptor) inhibitor as well as preparation method and pharmaceutical application thereof
Patent Information
- Application Number
- CN202380026722.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-23
- Filing Date
- 2023-07-24
- Publication Date
- 2024-11-22
AI Technical Summary
When faced with EGFR activating mutations, especially the C797X mutation, existing EGFR inhibitors have reduced efficacy and increased drug resistance, and there is a lack of effective targeted therapies, especially in osimertinib-resistant patients.
Develop a macrocyclic EGFR inhibitor targeting the double/triple mutations of EGFR L858R/C797S, Del19/C797S, L858R/T790M/C797S and Del19/T790M/C797S, with significant cytological activity for the treatment of related tumors and Metastatic disease.
This macrocyclic EGFR inhibitor shows potent inhibitory effects on specific EGFR mutant cells and has potential drug applications in the treatment and prevention of hyperproliferative diseases and cell death-inducing disorders. It may become an alternative to a new generation of EGFR inhibitors. .
Smart Images

Figure CN119013283A_ABST
Abstract
Description
Macrocyclic EGFR inhibitors and their preparation methods and pharmaceutical applications Technical Field
[0001] The present invention belongs to the field of drug synthesis, and specifically relates to a macrocyclic EGFR inhibitor, a preparation method thereof, and pharmaceutical applications thereof. Background Art
[0002] Lung cancer is the most lethal malignancy worldwide, posing a serious threat to human health. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. Numerous molecular mechanisms, including gene mutations and dysregulation, have been implicated in the pathogenesis of NSCLC, with EGFR being a major driver gene. The global frequency of activating EGFR mutations in NSCLC patients is approximately 17%, with East Asian populations being more susceptible, with a mutation frequency of approximately 50%. Activating EGFR mutations primarily occur in exons 18-21, with deletion mutations in exon 19 (Del19) and the L858R point mutation in exon 21 being the most common subtypes, accounting for over 80% of all mutations. These mutations can lead to ligand-independent receptor activation and promote tumor cell survival and proliferation. First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) primarily target these two activating mutations. Compared with platinum-based chemotherapy, first- and second-generation EGFR TKIs can significantly prolong progression-free survival, but resistance often develops after 10-12 months of treatment. EGFR T790M mutation is the primary mechanism of resistance to first- and second-generation EGFR TKIs. Subsequently, the third-generation EGFR TKI osimertinib was developed to selectively inhibit EGFR T790M and common EGFR mutations. In the results of the Phase III FLAURA study, osimertinib demonstrated superior efficacy compared to first-generation EGFR TKIs, significantly improving progression-free survival (18.9 vs. 10.2 months) and overall survival (38.6 vs. 31.8 months), which directly propelled osimertinib into the first-line treatment cohort.
[0003] Despite the significant efficacy of osimertinib, drug resistance inevitably occurs and leads to disease progression. Currently, there are no approved targeted therapies for patients who develop resistance to osimertinib. Several EGFR-dependent and -independent resistance mechanisms have been reported in both preclinical and clinical studies. The C797X (most common is C797S) mutation on exon 20 has become the most common EGFR-dependent osimertinib resistance mechanism. The C797X mutation is located in the tyrosine kinase region of EGFR, preventing osimertinib from forming a covalent bond within the ATP-binding domain of EGFR, thereby producing drug resistance. In the Phase III AURA3 trial, the incidence of C797X mutations in patients receiving second-line osimertinib treatment was 15%, while in the Phase III FLAURA trial, the incidence of C797X mutations in patients receiving first-line osimertinib treatment was 7%. Therefore, developing a next-generation EGFR inhibitor with better activity and selectivity, targeting the double mutation consisting of EGFR activating mutation / C797S and the triple mutation consisting of EGFR activating mutation / T790M / C797S, is crucial for patients who have become resistant to first-line or second-line osimertinib.
[0004] Summary of the Invention
[0005] The present invention aims to provide a macrocyclic EGFR inhibitor, its preparation method, and pharmaceutical applications. The compounds of this invention exhibit potent inhibitory effects on the cytological activity of EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation, and Del19 / T790M / C797S triple mutation. These compounds can be widely used in the preparation of drugs for treating and / or preventing tumors or metastatic diseases associated at least in part with EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation, and Del19 / T790M / C797S triple mutation, particularly for treating hyperproliferative diseases and disorders that induce cell death. These compounds are expected to contribute to the development of a new generation of EGFR inhibitors.
[0006] The first aspect of the present invention provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0007] in,
[0008] X1 for CR a or N;
[0009] X2 is CR b or N;
[0010] X3 for CR c or N;
[0011] X4 for CR d or N;
[0012] L1 is CR 5a R 5b ;
[0013] L2 is (CR 5c R 5d ) p NR 6a , O, S, S(O), S(O)2 or C(O);
[0014] L3 is key, CR 5e R 5f NR 6b , O, S, S(O), S(O)2 or C(O);
[0015] Alternatively, L2 and L3 together form C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl may be independently further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0016] L4 is CR 5g R 5h 、O、S、S(O)、S(O)2、NR 6c or C(O);
[0017] Ring A is C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0018] R1 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 3-12 Cycloalkyl substituted C 1-10 Alkyl, 3-12 membered heterocyclic substituted C 1-10 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0019] Each R2 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0020] Each R3, R a and R b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 ;
[0021] R4 and R c are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 ;
[0022] R d Selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 ;
[0023] R 5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 , or, R 5a and R 5b Together with the carbon atom directly connected to it, it forms a C(O), C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0024] Each R 5c and R 5d are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 , or, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14)R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent, provided that when R 5c or R 5d H or C 1-4 When alkyl, R1 is an optionally substituted C 2-10 Alkynyl, or L3 is O, S, S(O) or S(O)2;
[0025] R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 , or, R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13)R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0026] R 5g and R 5h are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 , or, R 5g and R 5h Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0027] R 6a Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 11 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 13 R 14 substituted by a substituent;
[0028] R 6b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 11 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 13 R 14 substituted by a substituent;
[0029] R 6c Selected from hydrogen, deuterium, C1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 11 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 13 R 14 substituted by a substituent;
[0030] Each R7 is independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)R 12 or -C 0-8 Alkyl-C(O)NR 13 R 14 The above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)R 12 、-C0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 or -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0031] Each R8 and R9 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, or, R8 and R9 together with the sulfur atom to which they are directly connected form a 3-10 membered heterocyclic group, the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 or -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0032] Each R 10 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 13 R 14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent;
[0033] Each R 11 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent;
[0034] Each R 12 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 13 R 14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent;
[0035] Each R 13 and R 14 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent;
[0036] Or, R 13and R 14 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, methylsulfonylmethyl, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent;
[0037] m is 0, 1, 2, 3 or 4;
[0038] n is 0, 1, or 2;
[0039] p is 1 or 2; and
[0040] Each r is independently 0, 1 or 2.
[0041] As a preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof,
[0042] X1 for CR a or N;
[0043] X2 is CR b or N;
[0044] X3 for CR c or N;
[0045] X4 for CR d or N;
[0046] L1 is CR 5a R 5b ;
[0047] L2 is (CR 5c R 5d ) p NR 6a , O, S, S(O), S(O)2 or C(O);
[0048] L3 is key, CR 5e R5f NR 6b , O, S, S(O), S(O)2 or C(O);
[0049] Alternatively, L2 and L3 together form C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、 -C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0050] L4 is CR 5g R 5h 、O、S、S(O)、S(O)2、NR 6c or C(O);
[0051] Ring A is C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl;
[0052] R1 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0053] Each R2 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0054] Each R3, R a and R b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 ;
[0055] R4 and Rc are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 ;
[0056] R d Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 ;
[0057] R 5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 , or, R 5a and R 5b Together with the carbon atom directly connected to it, it forms a C(O), C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0058] Each R 5c and R 5d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 , or, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent, provided that when R 5c or R 5d H or C 1-4 When alkyl, R1 is an optionally substituted C 2-10 Alkynyl, or L3 is O, S, S(O) or S(O)2;
[0059] R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 , or, R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0060] R 5g and R 5h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 , or, R 5g and R 5h Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0061] Among them, R 6a 、R 6b 、R 6c 、R7、R8、R9、R 10 、R 11 、R 12 、R 13 、R 14 , m, n, p and r are as defined for the compound of formula (I).
[0062] As a preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof,
[0063] Each R7 is independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)R 12 or -C 0-4 Alkyl-C(O)NR 13 R 14 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、 -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 or -C 0-4 Alkyl-N(R 13 )-C(O)R 12substituted by a substituent;
[0064] Each R8 and R9 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 aryl or 5-8 membered heteroaryl, or, R8 and R9 together with the sulfur atom to which they are directly connected form a 3-6 membered heterocyclic group, the above groups are optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 or -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0065] Each R 10 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 13 R14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent;
[0066] Each R 11 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent;
[0067] Each R 12 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 13 R 14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent;
[0068] Each R 13 and R 14 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent;
[0069] Or, R 13 and R 14 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-6 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, methylsulfonylmethyl, amino, mono C 1-4 Alkylamino, di-C1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; and
[0070] Each r is independently 0, 1 or 2.
[0071] As a further preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is the following compound of formula (II):
[0072] in,
[0073] X1 for CR a or N;
[0074] X2 is CR b or N;
[0075] X3 for CR c or N;
[0076] X4 for CR d or N;
[0077] L1 is CR 5a R 5b ;
[0078] L2 is (CR 5c R 5d ) p NR 6a , O, S, S(O), S(O)2 or C(O);
[0079] L3 is key, CR 5e R 5f or C(O);
[0080] L4 is CR 5g R 5h 、O、S、S(O)、S(O)2、NR 6c or C(O);
[0081] R1 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0082] R 2a Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-C(O)R 12 and -C(O)NR 13 R 14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0083] R 2b Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0084] R 3a 、R 3b 、R a and R b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 ;
[0085] R4 and R c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、 -S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 ;
[0086] R d Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14)R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 ;
[0087] R 5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 , or, R 5a and R 5b Together with the carbon atom directly connected to it, it forms a C(O), C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0088] Each R 5c and R 5d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 , or, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent, provided that when R 5c or R 5d H or C 1-4 When alkyl, R1 is an optionally substituted C 2-10 Alkynyl;
[0089] R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、 -SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 , or, R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0090] R 5g and R 5h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 , or, R 5g and R 5h Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0091] Among them, R 6a 、R 6c 、R7、R8、R9、R 10 、R 11 、R 12 、R 13 、R 14 , p and r are as defined for the compound of formula (I).
[0092] As a further preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is the following compound of formula (III):
[0093] in,
[0094] X1 for CR a or N;
[0095] X2 is CR b or N;
[0096] X3 for CR c or N;
[0097] X4 for CR d or N;
[0098] L1 is CR 5a R 5b ;
[0099] L2 is (CR 5c R 5d ) p ;
[0100] L3 is key, CR 5e R 5f or C(O);
[0101] L4 is CR 5g R 5h 、O、NR 6c or C(O);
[0102] R1 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent;
[0103] R 2a Selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0104] R 2b Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0105] R 3a 、R 3b 、R a and R b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5;
[0106] R c Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5;
[0107] R d Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5;
[0108] R 5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5, or R 5a and R 5b Together with the carbon atom directly connected to it, it forms a C(O), C3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0109] When p is 1, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, each of the above groups is independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 Substituents substituted by
[0110] Or, when p is 2, one of the sets R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, when one group R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 When the cycloalkyl group or the 4-6 membered heterocyclic group, the other group R 5c and R 5d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 ;
[0111] R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5, or R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0112] R 5g and R 5h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5, or R 5g and R 5h Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0113] R 6c Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 11 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 13 R 14 substituted by a substituent;
[0114] Among them, R7, R8, R9, R 10 、R 11 、R 12 、R 13 、R 14 , p and r are as defined for the compound of formula (I).
[0115] As a further preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is the following compound of formula (IV):
[0116] in,
[0117] L1 is CR 5a R 5b ;
[0118] L2 is CR 5c R 5d ;
[0119] L3 is CR 5e R 5f ;
[0120] L4 is O;
[0121] R1 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl and -SF5, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O)r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0122] R 2a Selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5;
[0123] R 2b Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -SF5, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5;
[0124] R5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R 5a and R 5b Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic ring, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5;
[0125] R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, each of the above groups is independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5;
[0126] R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, each of the above groups is independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5;
[0127] Among them, R7, R8, R9, R 10 、R11 、R 12 、R 13 、R 14 and r are as defined for the compound of formula (I).
[0128] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof,
[0129] L1 is CR 5a R 5b ;
[0130] L2 is CR 5c R 5d ;
[0131] L3 is CR 5e R 5f ;
[0132] L4 is O;
[0133] R 5a and R 5b each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl, each of which is optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5;
[0134] R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5; and
[0135] R 5e and R 5fEach is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano group, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl, and the above groups are each independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano group, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5.
[0136] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof,
[0137] R 2a is selected from hydrogen, deuterium, hydroxy, methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5; and
[0138] R 2b is selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl and -SF5, each of the above groups being independently further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5.
[0139] As a further preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is the following compound of formula (V):
[0140] in,
[0141] R1 is selected from C 2-4 Alkenyl, C 2-4 Alkynyl and 3-8 membered heterocyclic groups, each of which is independently optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, C2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, =O, =S, -SF5, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-NR 13 R 14 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)R 12 、-OC(O)R 12 、-NR 13 R 14 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0142] R 2a Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6Cycloalkyl and 3-6 membered heterocyclic groups, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 substituted by a cycloalkyl group or a 3-6 membered heterocyclic group;
[0143] R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, each of the above groups is independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5;
[0144] Among them, R 10 、R 11 、R 12 、R 13 、R 14 and r are as defined for the compound of formula (I).
[0145] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group.
[0146] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxolanyl or oxhexyl group.
[0147] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is C 2-4 Alkynyl, the C 2-4 Alkynyl is optionally further substituted with one or more radicals selected from deuterium, C 1-4 Alkyl, C 3-6 The substituents of cycloalkyl and 3-6 membered heterocyclic groups are substituted, each of the above groups being independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 The alkyl group is substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic group.
[0148] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is ethynyl, and the ethynyl group is optionally further substituted by one or more substituents selected from deuterium, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidine, azetyl and azohexyl. substituted, and the above groups are each independently further substituted by one or more substituents selected from deuterium, fluorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azetyl substituents.
[0149] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is ethynyl, and the ethynyl is optionally further substituted by one or more substituents selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azetyl substituents, and each of the above groups is independently optionally further substituted by one or more substituents selected from deuterium, fluorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl and trideuteriomethyl.
[0150] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is
[0151] R 1a is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl and trideuteriomethyl;
[0152] R 1b is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl and trideuteriomethyl.
[0153] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is a 4-8 membered nitrogen-containing heterocyclic group, and the 4-8 membered nitrogen-containing heterocyclic group is optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, =O, -N(R 13 )-S(O)2R 10 、-S(O) r R 10 、-OR 11 、-OC(O)R 12 、-NR 13 R 14 and -N(R 13 )-C(O)R 12 Substituents substituted, the C 1-4 The alkyl group is optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-OC(O)R 12 、-NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent;
[0154] Among them, R 10 、R 11 、R 12 、R 13 、R 14 and r are as defined for the compound of formula (I).
[0155] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is the following structure:
[0156] R 1c Selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the C 1-4The alkyl group is optionally further substituted with one or more radicals selected from deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -S(O) r R 10b AND-OR 11a substituted by a substituent;
[0157] R 1d Selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a ;
[0158] R 1e Selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the C 1-4 The alkyl group is optionally further substituted with one or more radicals selected from deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -S(O) r R 10b AND-OR 11a substituted by a substituent;
[0159] R 1f Selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the C 1-4 The alkyl group is optionally further substituted with one or more radicals selected from deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -S(O) r R 10b AND-OR 11a substituted by a substituent;
[0160] Each R 10a are independently selected from hydrogen, C 1-4 Alkyl, C 3-6Cycloalkyl and 3-6 membered heterocyclic groups;
[0161] Each R 10b are independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, C 1-4 Alkyl and C 1-4 substituted by an alkoxy substituent;
[0162] Each R 11a are independently hydrogen or C 1-4 alkyl;
[0163] Each R 12a are independently selected from hydrogen, C 1-4 Alkyl, C 1-4 Alkoxy and C 3-6 Cycloalkyl, each of the above groups independently being optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxyl and cyano;
[0164] Each R 13a are each independently hydrogen or C 1-4 alkyl; and
[0165] Each r is independently 0, 1 or 2.
[0166] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is the following structure:
[0167] R 1c Selected from hydrogen, deuterium, fluorine, bromine, methyl, ethyl, propyl, isopropyl, butyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the methyl, ethyl, propyl, isopropyl or butyl group is independently optionally further substituted with one or more selected from deuterium, methyl, ethyl, propyl, isopropyl, butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, -S(O) r R 10b AND-OR 11a substituted by a substituent;
[0168] R 1d is selected from the group consisting of hydrogen, deuterium, fluorine, bromine, methyl, ethyl, propyl, isopropyl and butyl;
[0169] R 1eSelected from hydrogen, deuterium, fluorine, bromine, methyl, ethyl, propyl, isopropyl, butyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the methyl, ethyl, propyl, isopropyl or butyl group is independently optionally further substituted with one or more selected from deuterium, methyl, ethyl, propyl, isopropyl, butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, -S(O) r R 10b AND-OR 11a substituted by a substituent;
[0170] Each R 10a independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl, and azohexyl;
[0171] Each R 10b independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azohexyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy and propoxy;
[0172] Each R 11a independently selected from hydrogen, methyl, ethyl, propyl, isopropyl and butyl;
[0173] Each R 12a independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, propoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl and cyano;
[0174] Each R 13a are each independently hydrogen;
[0175] Each r is independently 0, 1 or 2.
[0176] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is the following structure:
[0177] R1g is hydrogen, deuterium or methyl; R 1h is hydrogen, deuterium or methyl; R 1j is hydrogen, deuterium or methyl; q is 0, 1 or 2;
[0178] R 10a is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azohexyl;
[0179] R 10b selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azohexyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy and propoxy;
[0180] Each R 11a independently selected from hydrogen, methyl, ethyl, propyl, isopropyl and butyl;
[0181] R 12a is selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, propoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, each of which is independently further substituted by one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl and cyano.
[0182] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 2a Selected from hydrogen, deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 cycloalkyl and 3-6 membered heterocyclic groups.
[0183] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 2a is selected from hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl.
[0184] As the most preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof include but are not limited to the following compounds:
[0185] The second aspect of the present invention provides a method for preparing a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0186] wherein Ring A, X1, X2, X3, X4, L1, L2, L3, L4, R1, R2, R3, R4, m and n are as defined in the compound of formula (I).
[0187] The third aspect of the present invention provides a pharmaceutical composition comprising a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0188] The present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of drugs for treating and / or preventing tumors or metastatic diseases that are at least partially associated with EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation and Del19 / T790M / C797S triple mutation.
[0189] The present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of drugs for preventing and / or treating tumors and / or metastatic diseases caused by excessive proliferation and induction of cell death disorders.
[0190] The present invention also relates to the use of the aforementioned compound of formula (I), its stereoisomers or pharmaceutically acceptable salts in the preparation of a medicament for preventing and / or treating lung cancer, colon cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, uterine cancer, gastric cancer, non-small cell lung cancer, leukemia, myelodysplastic syndrome, malignant lymphoma, head and neck tumors, thoracic tumors, gastrointestinal tumors, endocrine tumors, breast and other gynecological tumors, urological tumors, skin tumors, sarcomas, nasal sinus inverted papilloma or nasal sinus squamous cell carcinoma associated with EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation and Del19 / T790M / C797S triple mutation.
[0191] The present invention also relates to the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof for use as a medicament.
[0192] The present invention also relates to the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, for use in treating and / or preventing tumors or metastatic diseases at least partially associated with EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation and Del19 / T790M / C797S triple mutation.
[0193] The present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof for preventing and / or treating tumors and / or metastatic diseases caused by excessive proliferation and induction of cell death disorders.
[0194] The present invention also relates to the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, for use in treating and / or preventing lung cancer, colon cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, uterine cancer, gastric cancer, non-small cell lung cancer, leukemia, myelodysplastic syndrome, malignant lymphoma, head and neck tumors, thoracic tumors, gastrointestinal tumors, endocrine tumors, breast and other gynecological tumors, urological tumors, skin tumors, sarcomas, sinonasal inverted papilloma or sinonasal squamous cell carcinoma associated with sinonasal inverted papilloma at least in part.
[0195] The present invention also relates to a method for treating and / or preventing tumors or metastatic diseases at least partially associated with EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation and Del19 / T790M / C797S triple mutation, which comprises administering a therapeutically effective amount of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof to a patient in need.
[0196] The present invention also relates to a method for preventing and / or treating tumors and / or metastatic diseases caused by excessive proliferation and induction of cell death disorders, which comprises administering a therapeutically effective amount of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof to a patient in need.
[0197] The present invention also relates to a method for treating and / or preventing lung cancer, colon cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, uterine cancer, gastric cancer, non-small cell lung cancer, leukemia, myelodysplastic syndrome, malignant lymphoma, head and neck tumors, thoracic tumors, gastrointestinal tumors, endocrine tumors, breast and other gynecological tumors, urological tumors, skin tumors, sarcomas, sinonasal inverted papilloma or sinonasal squamous cell carcinoma associated with sinonasal inverted papilloma at least in part and associated with EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation and Del19 / T790M / C797S triple mutation, which comprises administering to a patient in need thereof a therapeutically effective amount of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof. DETAILED DESCRIPTION
[0198] After extensive and in-depth research, the inventors of this application have developed, for the first time, an EGFR inhibitor having the structure of Formula (I). This series of compounds can be widely used to prepare medicaments for treating and / or preventing tumors or metastatic diseases associated with, at least in part, EGFR L858R / C797S double mutations, EGFR Del19 / C797S double mutations, L858R / T790M / C797S triple mutations, and Del19 / T790M / C797S triple mutations, and are expected to be developed into a new generation of EGFR inhibitors. Based on this, the present invention was completed.
[0199] Detailed Description: Unless otherwise stated or specifically indicated, the following terms used in the specification and claims have the following meanings.
[0200] "Alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group, preferably a straight-chain alkyl group and a branched alkyl group having 1 to 10, 1 to 6 or 1 to 4 carbon atoms, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl or various branched chain isomers thereof. “C 1-10 "Alkyl" refers to a straight chain alkyl group or a branched chain alkyl group containing 1 to 10 carbon atoms. 1-4 "Alkyl" refers to straight chain alkyl and branched chain alkyl groups containing 1 to 4 carbon atoms, "C 0-8 "Alkyl" refers to straight chain alkyl and branched chain alkyl groups including 0 to 8 carbon atoms, "C 0-4 The term "alkyl" refers to straight-chain and branched-chain alkyl groups having 0 to 4 carbon atoms.
[0201] Alkyl groups may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0202] "Cycloalkyl" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent. The partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system. Cycloalkyl is divided into monocyclic cycloalkyl and polycyclic cycloalkyl, preferably a cycloalkyl containing 3 to 12, 3 to 8 or 3 to 6 carbon atoms, for example, "C 3-12 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 12 carbon atoms, "C 4-12 "Cycloalkyl" refers to a cycloalkyl group comprising 4 to 12 carbon atoms, "C 4-8 "Cycloalkyl" refers to a cycloalkyl group comprising 4 to 8 carbon atoms, "C 3-8 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 8 carbon atoms, "C 3-6 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 6 carbon atoms, "C 4-6 "Cycloalkyl" refers to a cycloalkyl group comprising 4 to 6 carbon atoms, wherein:
[0203] Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like.
[0204] Polycyclic cycloalkyl groups include spiro, fused, and bridged cycloalkyl groups. "Spiroalkyl" refers to a polycyclic group in which the rings share a carbon atom (called a spiro atom). These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Spiroalkyl groups are classified as monospiroalkyl, bispiroalkyl, or polyspiroalkyl groups based on the number of spiro atoms shared between the rings. Spiroalkyl groups include, but are not limited to:
[0205] "Fused cycloalkyl" refers to an all-carbon polycyclic group in which each ring shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, fused cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused cycloalkyl groups include, but are not limited to:
[0206] "Bridged cycloalkyl" refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected. These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged cycloalkyl groups include, but are not limited to:
[0207] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl, including but not limited to indanyl, tetrahydronaphthyl, benzocycloheptanyl and the like.
[0208] Cycloalkyl may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0209] "Heterocyclyl" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein the partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, and one or more (preferably 1, 2, 3 or 4) ring atoms in the heterocyclyl are selected from N, O, N·O or S(O) r(wherein r is an integer of 0, 1, or 2), excluding the ring portion of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. Preferably, the heterocyclic group comprises 3 to 12, 3 to 8, or 3 to 6 ring atoms, for example, "3-6 membered heterocyclic group" refers to a heterocyclic group comprising 3 to 6 ring atoms, "3-8 membered heterocyclic group" refers to a heterocyclic group comprising 3 to 8 ring atoms, "4-6 membered heterocyclic group" refers to a heterocyclic group comprising 4 to 6 ring atoms, "4-8 membered heterocyclic group" refers to a heterocyclic group comprising 4 to 8 ring atoms, "4-10 membered heterocyclic group" refers to a heterocyclic group comprising 4 to 10 ring atoms, "4-12 membered heterocyclic group" refers to a heterocyclic group comprising 4 to 12 ring atoms, "5-8 membered heterocyclic group" refers to a heterocyclic group comprising 5 to 8 ring atoms, and "3-12 membered heterocyclic group" refers to a heterocyclic group comprising 3 to 12 ring atoms.
[0210] Monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, oxetanyl, tetrahydrofuranyl, and the like.
[0211] Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups. "Spiro heterocyclic group" refers to a polycyclic heterocyclic group in which the single rings share an atom (called a spiro atom), wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O). r (where r is an integer 0, 1, or 2) with the remaining ring atoms being carbon. These may contain one or more double bonds (preferably 1, 2, or 3), but no ring has a completely conjugated π electron system. Spiro heterocyclic groups are classified as monospiro heterocyclic groups, dispiro heterocyclic groups, or polyspiro heterocyclic groups based on the number of spiro atoms shared between the rings. Spiro heterocyclic groups include, but are not limited to:
[0212] "Fused heterocyclyl" refers to a polycyclic heterocyclic group in which each ring in the system shares a pair of adjacent atoms with the other rings in the system, one or more (preferably 1, 2, 3 or 4) rings may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r (where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, fused heterocyclic alkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused heterocyclic groups include, but are not limited to:
[0213] "Bridged heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, these may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r (where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, bridged heterocyclic groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged heterocyclic groups include, but are not limited to:
[0214] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, including but not limited to:
[0215] The heterocyclic group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0216] "Aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group, a polycyclic (i.e., rings with adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably an all-carbon aromatic group containing 6-10 or 6-8 carbon atoms, for example, "C 6-10 "Aryl" refers to an all-carbon aromatic group containing 6-10 carbon atoms, including but not limited to phenyl and naphthyl. 6-8 "Aryl" refers to an all-carbon aromatic group containing 6-8 carbon atoms. The aromatic ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aromatic ring, including but not limited to:
[0217] "Aryl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0218] "Heteroaryl" refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms, including N, O, N·O and S(O)r (wherein r is an integer of 0, 1 or 2), preferably a heteroaromatic system containing 5-10, 5-8 or 5-6 ring atoms, for example, "5-8 membered heteroaryl" refers to a heteroaromatic system containing 5-8 ring atoms, and "5-10 membered heteroaryl" refers to a heteroaromatic system containing 5-10 ring atoms, including but not limited to furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, including but not limited to:
[0219] "Heteroaryl" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0220] "Alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, preferably a straight or branched alkenyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkenyl" refers to a straight or branched chain alkenyl containing 2 to 10 carbon atoms. 2-4"Alkenyl" refers to a straight or branched chain alkenyl group containing 2 to 4 carbon atoms, including but not limited to ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc.
[0221] "Alkenyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0222] "Alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a straight or branched chain alkynyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkynyl" refers to a straight or branched chain alkynyl containing 2 to 10 carbon atoms. 2-4 "Alkynyl" refers to a straight or branched chain alkynyl containing 2-4 carbon atoms, including but not limited to ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, etc.
[0223] "Alkynyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0224] "Alkoxy" refers to an -O-alkyl group, wherein alkyl is as defined above, for example, "C 1-10 "Alkoxy" refers to an alkyloxy group containing 1 to 10 carbon atoms. 1-4 "Alkoxy" refers to an alkyloxy group containing 1 to 4 carbon atoms. 1-2 The term "alkoxy" refers to an alkyloxy group containing 1 to 2 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, butoxy, etc.
[0225] "Alkoxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0226] "Cycloalkoxy" or "cycloalkyloxy" refers to an -O-cycloalkyl group, wherein cycloalkyl is as defined above, for example, "C 3-12 "Cycloalkyloxy" refers to a cycloalkyloxy group containing 3 to 12 carbon atoms. 3-6 The term "cycloalkyloxy" refers to cycloalkyloxy groups containing 3 to 6 carbon atoms, including but not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0227] "Cycloalkoxy" or "cycloalkyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0228] "Heterocyclyloxy" or "heterocyclyloxy" refers to an -O-heterocyclyl group wherein heterocyclyl is as defined above and includes, but is not limited to, azetidinyloxy, oxetanyloxy, azopentyloxy, nitrogen, oxhexyloxy, and the like.
[0229] "Heterocyclyloxy" or "heterocyclyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent.
[0230] “C 1-10 "Alkanoyl" refers to C 1-10 The monovalent atomic group remaining after removing the hydroxyl group from the alkyl acid is usually expressed as "C 0-9 "C1 alkyl-C(O)-" refers to acetyl; "C2 alkyl-C(O)-" refers to propionyl; "C3 alkyl-C(O)-" refers to butyryl or isobutyryl.
[0231] "-C 0-8 Alkyl-S(O)(=N-R7)R8" refers to the sulfur atom in -S(O)(=N-R7)R8 attached to the C 0-8 On the alkyl group, where C 0-8The alkyl group is as defined above.
[0232] "-C 0-8 Alkyl-N=S(O)R8R9" refers to the nitrogen atom in -N=S(O)R8R9 connected to the C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0233] "-C 0-8 Alkyl-N=SR8R9" refers to the nitrogen atom in -N=SR8R9 connected to the C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0234] "-C 0-8 Alkyl-N(R 13 )-S(O)2R 10 ” refers to -N(R 13 )-S(O)2R 10 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0235] "-C 0-8 Alkyl-OS(O)2R 10 ” refers to -OS(O)2R 10 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0236] "-C 0-8 Alkyl-S(O) r R 10 ” refers to -S(O) r R 10 The sulfur atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0237] "-C 0-8 Alkyl-P(O)(R 12 )2” refers to -P(O)(R 12 )2 in which the phosphorus atom is connected to the C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0238] "-C 0-8 Alkyl-OR 11 " refers to -OR 11 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0239] "-C 0-8 Alkyl-C(O)OR 11 " refers to -C(O)OR 11 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.
[0240] "-C 0-8 Alkyl-C(O)SR 11 ” refers to -C(O)SR 11 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.
[0241] "-C 0-8 Alkyl-SC(O)R 12 ” refers to -SC(O)R 12 The sulfur atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0242] "-C 0-8 Alkyl-C(O)R 12 ” refers to -C(O)R 12 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.
[0243] "-C 0-8 Alkyl-OC(O)R 12 ” refers to -OC(O)R 12 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.
[0244] "-C 0-8 Alkyl-NR 13 R 14 ” refers to -NR 13 R 14 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.
[0245] "-C 0-8 Alkyl-C(=NR 13 )R 12 " refers to -C(=NR 13 )R 12 The carbon atoms in the 0-8 On the alkyl group, where C 0-8The alkyl group is as defined above.
[0246] "-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 ” refers to -N(R 13 )-C(=NR 14 )R 12 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0247] "-C 0-8 Alkyl-C(O)NR 13 R 14 ” refers to -C(O)NR 13 R 14 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0248] "-C 0-8 Alkyl-N(R 13 )-C(O)R 12 ” refers to -N(R 13 )-C(O)R 12 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0249] "Halogen-substituted C 1-10 The term "alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms, including but not limited to difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl and tribromomethyl.
[0250] "Halogen-substituted C 1-10 "Alkoxy" refers to an alkoxy group of 1-10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms. It includes but is not limited to difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, tribromomethoxy and the like.
[0251] "Deuterium replaces C 1-10 "Alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by deuterium atoms, including but not limited to monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, etc.
[0252] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0253] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur, i.e., includes both substituted and unsubstituted instances. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes both instances where the heterocyclic group is substituted with an alkyl group and where the heterocyclic group is not substituted with an alkyl group.
[0254] "Substituted" means that one or more "hydrogen atoms" in a group are independently replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, consistent with chemical valence theory, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated bonds (such as olefins).
[0255] "Stereoisomers," whose English name is stereoisomer, refer to isomers resulting from the different spatial arrangements of atoms in a molecule. They can be divided into two types: cis-trans isomers and enantiomers, or into two major categories: enantiomers and diastereomers. Stereoisomers caused by rotation about single bonds are called conformational stereoisomers, sometimes also called rotamers. Stereoisomers caused by bond length, bond angle, the presence of double bonds or rings in the molecule are called configuration stereoisomers, which are further divided into two categories. Among them, isomers caused by the inability to rotate freely around double bonds or single bonds of ring carbon atoms are called geometric isomers, also called cis-trans isomers, and are divided into two configurations: Z and E. For example, cis-2-butene and trans-2-butene are a pair of geometric isomers. Stereoisomers with different optical rotation properties due to the lack of anti-axial symmetry in the molecule are called optical isomers and are divided into R and S configurations. In the present invention, "stereoisomers," unless otherwise specified, are understood to include one or more of the aforementioned enantiomers, configurational isomers, and conformational isomers.
[0256] "Pharmaceutically acceptable salt" in the present invention refers to pharmaceutically acceptable acid addition salts, including inorganic acid salts and organic acid salts, which can be prepared by methods known in the art.
[0257] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0258] The present invention will be further described in detail and completely below with reference to the embodiments, but the present invention is by no means limited thereto, and the present invention is not limited to the contents of the embodiments.
[0259] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using a Bruker AVANCE-400 / 500 NMR spectrometer, using deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), and deuterated chloroform (CDCl3) as the solvents, with tetramethylsilane (TMS) as the internal standard.
[0260] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 6120 mass spectrometer. HPLC was performed using an Agilent 1200DAD high-pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high-pressure liquid chromatograph (Gimini C18 150×4.6 mm column).
[0261] Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
[0262] The starting materials in the examples of the present invention are known and can be purchased commercially, or can be synthesized using or according to methods known in the art.
[0263] Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, with dry solvents and reaction temperatures expressed in degrees Celsius (°C).
[0264] 1. Preparation of intermediates
[0265] Intermediate 1-1: Preparation of (S)-3-bromo-1-(4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-1H-pyrazolo[4,3-c]pyridine
[0266] Step 1: Synthesis of 3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridine
[0267] 6-Chloro-1H-pyrazolo[4,3-c]pyridine (5.0 g, 32.56 mmol) was dissolved in DMF (30 mL), and NBS (6.95 g, 39.07 mmol) was added. The mixture was stirred at room temperature for 2 hours. CH2Cl2 and saturated aqueous NaHCO3 were added for extraction. The organic phase was washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was separated by silica gel column chromatography to give 3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridine (7.4 g, yield: 97.8%).
[0268] Step 2: Synthesis of (R)-4-((tert-butyldimethylsilyl)oxy)butan-2-ol
[0269] (R)-Butane-1,3-diol (4.98 mL, 55.48 mmol) was dissolved in CH2Cl2 (80 mL), and imidazole (4.16 g, 61.03 mmol) was added. The mixture was cooled to 0°C, and then TBSCl (8.36 g, 55.48 mmol) was added. The reaction was stirred at 10°C for 3 hours. The mixture was diluted with CH2Cl2 and water, and the organic phase was separated by extraction, washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was separated by silica gel column chromatography to yield (R)-4-((tert-butyldimethylsilyl)oxy)butan-2-ol (9.0 g, yield: 79.4%).
[0270] Step 3: Synthesis of (R)-4-((tert-butyldimethylsilyl)oxy)butan-2-yl 4-methylbenzene-1-sulfonate
[0271] (R)-4-((tert-Butyldimethylsilyl)oxy)butan-2-ol (6.0 g, 29.36 mmol) was dissolved in pyridine (60 mL), followed by the addition of DMAP (1.08 g, 8.81 mmol). TsCl (12.31 g, 64.59 mmol) was added while cooling to 0°C. After the addition, the mixture was stirred at room temperature for 18 hours. The mixture was diluted with CH2Cl2 and water, and the organic phase was separated by extraction, washed with a saturated aqueous NaCl solution, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was separated by silica gel column chromatography to yield (R)-4-((tert-Butyldimethylsilyl)oxy)butan-2-yl 4-methylbenzene-1-sulfonate (6.4 g, yield: 60.8%).
[0272] Step 4: Synthesis of (S)-3-bromo-1-(4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-1H-pyrazolo[4,3-c]pyridine
[0273] 3-Bromo-6-chloro-1H-pyrazolo[4,3-c]pyridine (1.0 g, 4.30 μmol) was dissolved in DMF (20 mL), followed by the addition of (R)-4-((tert-butyldimethylsilyl)oxy)butan-2-yl 4-methylbenzene-1-sulfonate (1.85 g, 5.16 mmol) and Cs2CO3 (2.80 g, 8.60 mmol). The mixture was heated and stirred at 45°C for 18 hours. After cooling to room temperature, the mixture was extracted with EtOAc and water. The organic phase was washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography to afford (S)-3-bromo-1-(4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-1H-pyrazolo[4,3-c]pyridine (1.5 g, yield: 83.3%). MS m / z(ESI):418.2 / 420.2[M+H] + .
[0274] Intermediates 1-2 to 1-6 can be prepared by selecting corresponding raw materials according to the synthesis method of intermediate 1-1.
[0275] Intermediate 1-7: Preparation of (1-((3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol
[0276] Step 1: Synthesis of methyl 1-(iodomethyl)cyclopentane-1-carboxylate
[0277] Methyl cyclopentanecarboxylate (11.7 g, 91.285 mmol) was dissolved in THF (120 mL). Under nitrogen, a LDA / THF solution (54.8 mL, 109.542 mmol, 2 M) was slowly added dropwise at -78°C, followed by CH₂I₂ (8.837 mL, 109.542 mmol). After addition, the mixture was allowed to warm to room temperature and react for 1.5 hours. TLC confirmed the reaction was complete. The mixture was quenched with saturated aqueous NH₄Cl (150 mL). The mixture was extracted three times with EtOAc (100 mL). The organic phases were combined and dried over anhydrous Na₂SO₄. The residue was filtered and concentrated to afford methyl 1-(iodomethyl)cyclopentane-1-carboxylate (23.5 g, 78.891 mmol, yield: 86.4%).
[0278] 1 H NMR (400MHz, CDCl3) δ3.72 (d, J = 0.9 Hz, 3H), 3.41 (d, J = 0.9 Hz, 2H), 2.26–2.16 (m, 2H), 1.79–1.61 (m, 6H).
[0279] Step 2: Synthesis of methyl 1-((3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentane-1-carboxylate
[0280] 3-Bromo-6-chloro-1H-pyrazolo[4,3-c]pyridine (37.46 g, 161.140 mmol) and methyl 1-(iodomethyl)cyclopentane-1-carboxylate (43.2 g, 161.14 mmol) were dissolved in DMF (800 mL). K2CO3 (44.54 g, 322.28 mmol) was added, and the mixture was heated to 100°C and stirred for 16 hours. TLC confirmed the reaction was complete. The reaction mixture was cooled to room temperature and concentrated. The residue was separated by silica gel column chromatography [eluent: PE / EA5 / 1] to afford methyl 1-((3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentane-1-carboxylate (38.5 g, 103.31 mmol, yield: 64.1%). MS m / z(ESI):372.0,374.0[M+H] + .
[0281] Step 3: Synthesis of (1-((3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol
[0282] Methyl 1-((3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentane-1-carboxylate (8.5 g, 22.81 mmol) was dissolved in CHCl (100 mL) and cooled to -78°C. DIBAL-H (45.62 mL, 45.62 mmol) was slowly added at low temperature and stirred at -78°C for 2 hours. TLC confirmed the reaction was complete. Saturated brine was added to quench the reaction, followed by aqueous potassium sodium tartrate (50 mL) and stirring at room temperature for 10 minutes. The mixture was then extracted three times with CHCl (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was separated by silica gel column chromatography [eluent: PE / EA = 2 / 1] to give (1-((3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol (5.8 g, 16.83 mmol, yield: 73.78%). MS m / z (ESI): 344.0, 346.0 [M+H] + .
[0283] Intermediates 1-8 to 1-10 were prepared by selecting corresponding raw materials according to the synthetic route of intermediate 1-7.
[0284] Intermediate 2-1: Preparation of (S)-1-(4-((tert-butyldimethylsilyl)oxy)but-2-yl)-6-chloro-3-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridine
[0285] (S)-3-Bromo-1-(4-((tert-butyldimethylsilyl)oxy)but-2-yl)-6-chloro-1H-pyrazolo[4,3-c]pyridine (0.90 g, 2.14 mmol) was dissolved in DMF (10 mL), followed by the addition of Pd(PPh3)2Cl2 (0.31 g, 0.43 mmol), CuI (164 mg, 0.86 mmol), and Et3N (3 mL). Under nitrogen, propyne solution (10 mL g, 10 mmol) was added via syringe, and the mixture was heated to 70°C and allowed to react overnight. After completion of the reaction, EtOAc was added for dilution, and the organic phase was washed sequentially with water and saturated brine, and dried over anhydrous sodium sulfate. The filtrate was filtered, concentrated, and then separated by column chromatography to obtain (S)-1-(4-((tert-butyldimethylsilyl)oxy)but-2-yl)-6-chloro-3-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridine (0.77 g, yield: 80%). MS m / z (ESI): 378.2 [M+H] + .
[0286] Intermediate 2-2: Preparation of 1-((S)-4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-3-(((S)-1-methylpyrrolidin-2-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridine
[0287] Step 1: Synthesis of tert-butyl (S)-2-ethynylpyrrolidine-1-carboxylate
[0288] (S)-tert-Butyl 2-formylpyrrolidine-1-carboxylate (5.0 g, 25.09 mmol) was dissolved in MeOH (50 mL), followed by the addition of K2CO3 (6.94 g, 50.19 mmol). The mixture was cooled to 0°C, and dimethyl (1-diazo-2-oxopropyl)phosphate (5.65 mL, 37.64 mmol) was added dropwise. The mixture was allowed to react at room temperature for 18 hours. After completion of the reaction, the mixture was filtered, the filtrate was concentrated, and column chromatography was performed to obtain tert-butyl (S)-2-ethynylpyrrolidine-1-carboxylate (4.4 g, yield: 89.8%). MS m / z (ESI): 195.8 [M+H] + .
[0289] Step 2: Synthesis of tert-butyl (S)-2-((1-((S)-4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)ethynyl)pyrrolidine-1-carboxylate
[0290] (S)-3-Bromo-1-(4-((tert-butyldimethylsilyl)oxy)but-2-yl)-6-chloro-1H-pyrazolo[4,3-c]pyridine (0.6 g, 1.43 mmol) was dissolved in DMF (20 mL), followed by the addition of (S)-tert-butyl 2-ethynylpyrrolidine-1-carboxylate (1119 mg, 5.73 mmol), CuI (0.27 g, 1.43 mmol), Et3N (1.0 mL, 7.16 mmol), and Pd(PPh3)4 (0.50 g, 0.43 mmol). The mixture was heated at 80°C for 2 hours under nitrogen protection. The mixture was cooled to room temperature, filtered, and the filtrate was poured into water and extracted with EtOAc. The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, the filtrate was concentrated, and then column chromatography was used to separate (S)-tert-butyl 2-((1-((S)-4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)ethynyl)pyrrolidine-1-carboxylate (720 mg, yield: 94.3%). MS m / z (ESI): 533.4 [M+H] + .
[0291] Step 3: Synthesis of 1-((S)-4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-3-(((S)-pyrrolidin-2-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridine
[0292] Tert-butyl (S)-2-((1-((S)-4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)ethynyl)pyrrolidine-1-carboxylate (720 mg, 1.35 mmol) was dissolved in hexafluoroisopropanol (20 mL), and then TFA (1.0 mL, 13.50 mmol) was added dropwise. The reaction was allowed to react at room temperature for 1 hour. After completion of the reaction, CH2Cl2 was added for dilution, and the mixture was washed sequentially with saturated aqueous NaHCO3 solution, pure water, and saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated to obtain a crude product, which was used directly in the next step. MS m / z (ESI): 433.2 [M+H] + .
[0293] Step 4: Synthesis of 1-((S)-4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-3-(((S)-1-methylpyrrolidin-2-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridine
[0294] 1-((S)-4-((tert-Butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-3-(((S)-pyrrolidin-2-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridine (550 mg, 1.27 mmol) was dissolved in CHCl (20 mL), followed by the addition of formaldehyde (1271 mg, 12.7 mmol) and NaBH(OAc) (1346 mg, 6.35 mmol). The mixture was allowed to react at room temperature for 3 hours. After completion of the reaction, CHCl was added for dilution, and the product was washed sequentially with saturated aqueous NaHCO, pure water, and saturated brine, and then dried over anhydrous sodium sulfate. The mixture was filtered, the filtrate was concentrated, and column chromatography was used to separate 1-((S)-4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-6-chloro-3-(((S)-1-methylpyrrolidin-2-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridine (350 mg, yield: 61.6%). MS m / z (ESI): 447.2 [M+H] + .
[0295] Intermediate 2-3: Preparation of (1-((6-chloro-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol
[0296] Step 1: Synthesis of tert-butyl 4-((1-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopentyl)methyl)-6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)ethynyl)piperidine-1-carboxylate
[0297] 3-Bromo-1-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopentyl)methyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine (375 mg, 0.817 mmol) was dissolved in DMF (20 mL), and then tert-butyl 4-ethynylpiperidine-1-carboxylate (256.5 mg, 1.226 mmol), CuI (62.3 mg, 0.327 mmol), Et3N (1.14 mL, 8.172 mmol) and Pd(PPh3)2Cl2 (114.7 mg, 0.163 mmol) were added, and the mixture was heated at 80°C with stirring overnight under nitrogen protection. After completion of the reaction, the reaction solution was concentrated and separated by column chromatography to obtain tert-butyl 4-((1-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopentyl)methyl)-6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)ethynyl)piperidine-1-carboxylate (450 mg, 0.766 mmol, yield: 93.8%). MS m / z (ESI): 587.4 [M+H] + .
[0298] Step 2: Synthesis of (1-((6-chloro-3-(piperidin-4-ylethynyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol
[0299] Tert-butyl 4-((1-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopentyl)methyl)-6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)ethynyl)piperidine-1-carboxylate (450 mg, 0.766 mmol) was dissolved in CHCl (15 mL), followed by the dropwise addition of TFA (0.57 mL, 7.662 mmol), and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was added with saturated aqueous sodium bicarbonate and extracted with dichloromethane. The combined organic phases were washed sequentially with water and saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated to afford the crude product (1-((6-chloro-3-(piperidin-4-ylethynyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol (260 mg, 0.697 mmol, yield: 91.0%). MS m / z(ESI):373.2[M+H] + .
[0300] Step 3: Synthesis of (1-((6-chloro-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol
[0301] (1-((6-chloro-3-(piperidin-4-ylethynyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol (260 mg, 0.697 mmol) was dissolved in CH2Cl2 (20 mL), followed by the addition of 33% aqueous formaldehyde solution (299 mg, 3.486 mmol) and NaBH(OAc)3 (739 mg, 3.486 mmol), and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, saturated aqueous NaHCO3 was added to quench the reaction, and the mixture was extracted three times with dichloromethane. The organic phases were combined, concentrated, and then separated by column chromatography to give (1-((6-chloro-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol (260 mg, 0.672 mmol, yield: 96.4%). MS m / z(ESI):387.2[M+H] + .
[0302] Intermediates 2-4 to 2-23 can be prepared by selecting corresponding raw materials according to the synthesis method of intermediate 2-2 or 2-3.
[0303] Intermediate 3-1: Preparation of tert-butyl 3-((methylsulfonyl)methyl)azetidine-1-carboxylate
[0304] Tert-butyl 3-iodoazetidine-1-carboxylate (5.00 g, 16.83 mmol) was dissolved in DMF (30 mL), and sodium methanesulfinate (2.58 g, 25.24 mmol) was added. The mixture was heated at 70°C and stirred for 3 hours. After the reaction, ethyl acetate was added to dilute the mixture, and the mixture was washed sequentially with water and saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered, the filtrate was concentrated, and column chromatography was performed to obtain tert-butyl 3-((methylsulfonyl)methyl)azetidine-1-carboxylate (3.20 g, yield: 68%).
[0305] 1 HNMR (400MHz, DMSO-d6) δ3.97(t,2H),3.70(d,2H),3.48(d,J=7.5Hz,2H),3.04–2.99(m,1H),2.95(s,3H),1.37(s,9H).
[0306] Intermediate 3-2: Preparation of tert-butyl (S)-3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidine-1-carboxylate
[0307] Step 1: Synthesis of tert-butyl (S)-3-(((trifluoromethyl)thio)methyl)pyrrolidine-1-carboxylate
[0308] Tetrabutylammonium iodide (132.14 g, 357.73 mmol) and AgSCF3 (25.03 g, 119.24 mmol) were added to toluene (300 mL). Under nitrogen, tert-butyl (S)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (6.0 g, 29.81 mmol) was added and heated at 120°C overnight. The reaction solution was filtered through silica gel and rinsed three times with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated. Column chromatography (petroleum ether / ethyl acetate = 0-20%) was used to separate tert-butyl (S)-3-(((trifluoromethyl)thio)methyl)pyrrolidine-1-carboxylate (5.0 g, purity: 93.0%, yield: 54.6%). MS m / z (ESI): 230.1 [M-56] + .
[0309] 1 HNMR (400MHz, CDCl3) δ3.67–3.38(m,2H),3.38–3.25(m,1H),3.04(q,J=10.0,9.6Hz,1H),2.91(t, J=7.6Hz,2H),2.47(q,J=7.6Hz,1H),2.10(tt,J=7.6,3.6Hz,1H),1.69–1.56(m,1H),1.45(s,9H).
[0310] Step 2: Synthesis of tert-butyl (S)-3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidine-1-carboxylate
[0311] To a solution of tert-butyl (S)-3-(((trifluoromethyl)thio)methyl)pyrrolidine-1-carboxylate (5.0 g, 17.52 mmol) in dichloromethane (20 mL), acetonitrile (20 mL), and water (20 mL) were added ruthenium trichloride hydrate (0.79 g, 3.51 mmol) and sodium periodate (11.24 g, 52.57 mmol) at room temperature. The reaction mixture was diluted with water and extracted three times with dichloromethane. The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The product was filtered, concentrated, and separated by column chromatography to afford tert-butyl (S)-3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidine-1-carboxylate (2.9 g, yield: 52.1%). MS m / z (ESI): 262.0 [M-56] + .
[0312] Intermediate 3-3: Preparation of tert-butyl (S)-3-((ethylsulfonyl)methyl)pyrrolidine-1-carboxylate
[0313] Step 1: Synthesis of tert-butyl (S)-3-((toluenesulfonyloxy)methyl)pyrrolidine-1-carboxylate
[0314] tert-Butyl (S)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (15.0 g, 74.53 mmol) was dissolved in CH2Cl2 (200 mL), followed by the addition of DMAP (4.55 g, 37.26 mmol) and Et3N (31 mL, 223.58 mmol). TsCl (21.31 g, 111.79 mmol) was added at 0°C and allowed to react at room temperature for 3 hours. Water and dichloromethane were added to the reaction mixture, and the layers were separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined, washed sequentially with saturated brine, and dried over anhydrous sodium sulfate. The product was filtered, concentrated, and separated by column chromatography to afford tert-butyl (S)-3-((tosyloxy)methyl)pyrrolidine-1-carboxylate (23.5 g, yield: 88.7%).
[0315] 1 HNMR (400MHz, CDCl3) δ7.78(d,J=8.3Hz,2H),7.35(d,J=7.9Hz,2H),3.95(qd,J=9.8,7.0Hz,2H),3.45(dd,J=11.2,7.5Hz,1H),3. 40–3.22(m,2H),3.00(dd,J=11.2,6.9Hz,1H),2.53(dq,J=14.4,7.2Hz,1H),2.45(s,3H),1.94(s,1H),1.65(s,1H),1.43(s,9H).
[0316] Step 2: Synthesis of tert-butyl (S)-3-((ethylsulfonyl)methyl)pyrrolidine-1-carboxylate
[0317] Tert-butyl (S)-3-((tosyloxy)methyl)pyrrolidine-1-carboxylate (8.0 g, 22.51 mmol) was dissolved in DMF (60 mL). Potassium iodide (11.21 g, 67.52 mmol) and sodium ethanesulfinate (7.84 g, 67.52 mmol) were added sequentially. The mixture was heated to 120°C for 2 hours. The mixture was cooled to room temperature, concentrated, and separated by column chromatography to afford tert-butyl (S)-3-((ethylsulfonyl)methyl)pyrrolidine-1-carboxylate (5.4 g, yield: 86.5%).
[0318] Intermediate 3-4: Preparation of tert-butyl (S)-3-((cyclobutylsulfonyl)methyl)pyrrolidine-1-carboxylate
[0319] Step 1: Synthesis of cyclobutanesulfonyl chloride
[0320] To anhydrous tetrahydrofuran (5 mL) was added magnesium turnings (0.41 g, 8.33 mmol), followed by cyclobutyl bromide (0.30 g, 2.22 mmol) and iodine (0.14 g, 0.56 mmol). The mixture was heated with a hair dryer while stirring until the reaction mixture turned colorless. The remaining cyclobutyl bromide (1.20 g, 8.89 mmol) in tetrahydrofuran (15 mL) was slowly added dropwise. After addition, the mixture was refluxed for 1 hour, cooled to room temperature, and set aside as a suspension. Under nitrogen, a solution of chlorosulfonyl chloride (2.70 mL, 33.34 mmol) in anhydrous dichloromethane (10 mL) was cooled to 0°C, and the above suspension was slowly added. After addition, the mixture was warmed to room temperature and reacted for 1 hour. The reaction solution was concentrated to dryness, and n-heptane (25 mL) was added to slurry, filtered, and the filtrate was concentrated to dryness to obtain crude cyclobutanesulfonyl chloride (0.95 g, yield: 55.2%), which was directly used for the next reaction.
[0321] Step 2: Synthesis of Sodium Cyclobutanesulfinate
[0322] A solution of sodium sulfite (1.55 g, 12.29 mmol) in water (10 mL) was heated to 80°C, and crude cyclobutanesulfonyl chloride (0.95 g, 6.14 mmol) and sodium carbonate (1.30 g, 12.29 mmol) were added in sequence. The mixture was kept at 80°C for 1 hour and then concentrated to dryness. Methanol was added for pulping, and the mixture was filtered. The filtrate was concentrated to dryness to obtain crude sodium cyclobutanesulfinate (0.86 g, yield: 98.5%), which was directly used for the next step.
[0323] Step 3: Synthesis of tert-butyl (S)-3-((cyclobutylsulfonyl)methyl)pyrrolidine-1-carboxylate
[0324] To a solution of tert-butyl (S)-3-((tosyloxy)methyl)pyrrolidine-1-carboxylate (0.80 g, 2.25 mmol) in N,N-dimethylformamide (10 mL) were added potassium iodide (1.0 g, 6.02 mmol) and crude sodium cyclobutanesulfinate (0.86 g, 6.08 mmol) sequentially at room temperature. The mixture was heated to 120°C and reacted for 2 hours. The reaction solution was concentrated and separated by column chromatography [petroleum ether / ethyl acetate = 0-15%] to afford tert-butyl (S)-3-((cyclobutanesulfonyl)methyl)pyrrolidine-1-carboxylate (0.50 g, yield: 73.2%).
[0325] 1 HNMR (400MHz, CDCl3) δ3.80–3.65(m,2H),3.47(ddd,J=14.0,7.3,3.0Hz,1H),3.30(ddt,J=11.0,8.9,5.4Hz,1H),3.05(dd,J=10.9,8.1Hz ,1H),2.89(s,1H),2.82–2.66(m,1H),2.65–2.51(m,2H),2.35–2.17(m,3H),2.07(tt,J=9.9,3.7Hz,2H),1.84–1.60(m,2H),1.44(s,9H).
[0326] Intermediates 3-5 to 3-15 were prepared by referring to part of the route of intermediate 3-3 or 3-4, and selecting corresponding raw materials.
[0327] Intermediate 4-1: Preparation of 1-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methyl)-6-chloro-3-(3-((methylsulfonyl)methyl)azetidin-1-yl)-1H-pyrazolo[4,3-c]pyridine
[0328] Step 1: Synthesis of 3-((methylsulfonyl)methyl)azetidine hydrochloride
[0329] Tert-butyl 3-((methylsulfonyl)methyl)azetidine-1-carboxylate (3.90 g, 15.64 mmol) was dissolved in 1,4-dioxane (4.0 mL). Hydrochloric acid (4.0 mL, 16.0 mmol) was added and stirred at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated to afford 3-((methylsulfonyl)methyl)azetidine hydrochloride (3.30 g, 90% yield).
[0330] 1 HNMR (400MHz, MeOH-d4) δ4.07–3.97(m,2H),3.89–3.79(m,2H),3.60(d,J=7.6Hz,2H),3.31–3.23(m,1H),3.00(s,3H).
[0331] Step 2: Synthesis of 1-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methyl)-6-chloro-3-(3-((methylsulfonyl)methyl)azetidin-1-yl)-1H-pyrazolo[4,3-c]pyridine
[0332] 3-Bromo-1-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine (0.60 g, 1.24 mmol) was added to 1,4-dioxane (15.0 mL), followed by 3-((methylsulfonyl)methyl)azetidine hydrochloride (0.35 g, 1.86 mmol), Cs2CO3 (1.21 g, 3.72 mmol), and Xantphos Pd-G3 (0.35 g, 0.37 mmol). The mixture was heated at 80°C under nitrogen and reacted overnight. After the reaction was complete, the mixture was cooled to room temperature, quenched by the addition of saturated brine, and extracted with EtOAc. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the residue was separated by column chromatography to give 1-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methyl)-6-chloro-3-(3-((methylsulfonyl)methyl)azetidin-1-yl)-1H-pyrazolo[4,3-c]pyridine (0.50 g, purity: 58.5%, yield: 45.7%). MS m / z (ESI): 513.2 [M+H] + .
[0333] Intermediate 4-2: Preparation of (S)-(1-((6-chloro-3-(3-((ethylsulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol
[0334] Step 1: Synthesis of (S)-3-((ethylsulfonyl)methyl)pyrrolidine hydrochloride
[0335] Tert-butyl (S)-3-((ethylsulfonyl)methyl)pyrrolidine-1-carboxylate (5.4 g, 19.47 mmol) was dissolved in 1,4-dioxane (15 mL). HCl / 1,4-dioxane solution (14.6 mL, 4 M, 58.40 mmol) was slowly added dropwise. The mixture was allowed to react at room temperature for 1 hour. After completion of the reaction, the solution was concentrated to afford crude (S)-3-((ethylsulfonyl)methyl)pyrrolidine hydrochloride (3.75 g, 90.1% yield), which was used directly in the next step.
[0336] Step 2: Synthesis of methyl (S)-1-((6-chloro-3-(3-((ethylsulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentane-1-carboxylate
[0337] (S)-3-((Ethylsulfonyl)methyl)pyrrolidine hydrochloride (0.34 g, 1.61 mmol) and methyl 1-((3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentane-1-carboxylate (0.40 g, 1.07 mmol) were dissolved in 1,4-dioxane (8 mL). Cs2CO3 (1.40 g, 4.29 mmol) and xantphos Pd-G3 (0.15 g, 0.16 mmol) were then added. After nitrogen was replaced, the mixture was microwave-heated at 85°C for 4 hours. The reaction mixture was cooled and diluted with ethyl acetate. The mixture was then washed once with water and once with saturated brine. The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the resulting crude product was separated by column chromatography to give methyl (S)-1-((6-chloro-3-(3-((ethylsulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentane-1-carboxylate (0.33 g, purity: 77.5%, yield: 51.2%). MS m / z (ESI): 469.2 [M+H] + .
[0338] Step 3: Synthesis of (S)-(1-((6-chloro-3-(3-((ethylsulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol
[0339] (S)-1-((6-chloro-3-(3-((ethylsulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentane-1-carboxylate (0.60 g, 0.99 mmol) was dissolved in dichloromethane (8 mL), cooled to -78°C, and DIBAL-H solution (4.06 mL, 1.0 M, 4.06 mmol) was slowly added dropwise. The reaction was maintained at this temperature for 1 hour. Saturated aqueous ammonium chloride was added to the reaction solution to quench the reaction, followed by extraction twice with dichloromethane. The organic phases were combined, washed sequentially with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the resulting crude product was separated by column chromatography (eluent: CH2Cl2 / MeOH 0-3%) to give (S)-(1-((6-chloro-3-(3-((ethylsulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol (0.43 g, purity: 87.0%, yield: 85.6%). MS m / z (ESI): 441.2 [M+H] + .
[0340] Intermediates 4-3 to 4-23 can be prepared by selecting corresponding raw materials according to the synthesis method of intermediate 4-1 or 4-2.
[0341] Intermediate 5-1: Preparation of 4-(4-aminopyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one
[0342] Step 1: Synthesis of 2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one
[0343] 2-Methyl-2,3-dihydro-1H-pyrazol-3-one (6.0 g, 61.16 mmol) was dissolved in CH3CN (80 mL), followed by the addition of K2CO3 (36.0 g, 260.52 mmol) and SEMCl (22.0 mL, 124.15 mmol). The reaction was stirred at room temperature for 18 hours. The mixture was filtered and the filtrate concentrated. The solid was slurried in a PE / EA (10:1) mixture, filtered, and dried under vacuum to yield 2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (12.1 g, yield: 82.3%).
[0344] Step 2: Synthesis of 4-bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one
[0345] 2-Methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (12.1 g, 52.98 mmol) was dissolved in CH3CN (250 mL), cooled to 0°C, and NBS (14.15 g, 79.48 mmol) was added. The mixture was stirred at room temperature for 3 hours. After the reaction was complete, saturated aqueous Na2S2O3 was added to quench the reaction, and the mixture was extracted with CH2Cl2. The organic phase was washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was slurried in a mixture of PE / EA (10:1), filtered, and the solid was dried under vacuum to yield 4-bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (12.00 g, yield: 70%).
[0346] Step 3: Synthesis of tert-butyl (tert-butyloxycarbonyl)(2-chloropyrimidin-4-yl)carbamate
[0347] 2-Chloropyrimidin-4-amine (8.00 g, 61.75 mmol) was dissolved in THF (100 mL), and DMAP (0.75 g, 6.18 mmol), Et3N (34.3 mL, 247.0 mmol), and Boc2O (40.43 g, 185.26 mmol) were added. The reaction was stirred at room temperature for 18 hours. After the reaction was complete, EtOAc and water were added for dilution, and the organic phase was extracted. The organic phase was washed with a saturated aqueous NaCl solution, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was slurried in petroleum ether, filtered, and the filter cake was dried under vacuum to give tert-butyl (tert-butyloxycarbonyl)(2-chloropyrimidin-4-yl)carbamate (19.72 g, yield: 92%).
[0348] Step 4: Synthesis of tert-butyl (tert-butyloxycarbonyl)(2-(2-methyl-3-oxy-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)pyrimidin-4-yl)carbamate
[0349] 4-Bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (0.5 g, 1.63 mmol) was dissolved in a mixture of CH3CN / H2O (25 / 2.5 mL), and tert-butyl (tert-butyloxycarbonyl)(2-chloropyrimidin-4-yl)carbamate (2.68 g, 8.14 mmol), B2Pin2 (2.11 mL, 8.14 mmol), Na2CO3 (0.86 g, 8.14 mmol), and Pd(Amphos)2Cl2 (0.23 g, 0.33 mmol) were added. The mixture was heated at 100°C under nitrogen for 4 hours. After the reaction was complete, the mixture was cooled to room temperature and extracted with EtOAc and H2O. The organic phase was washed with saturated aqueous NaCl solution, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was separated by column chromatography to give tert-butyl (tert-butoxycarbonyl)(2-(2-methyl-3-oxy-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)pyrimidin-4-yl)carbamate (580 mg, yield: 47.8%).
[0350] Step 5: Synthesis of 4-(4-aminopyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one
[0351] Tert-butyl (tert-butoxycarbonyl)(2-(2-methyl-3-oxy-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)pyrimidin-4-yl)carbamate (1.4 g, 2.68 mmol) was dissolved in hexafluoroisopropanol (15 mL), and TFA (2.8 mL, 37.57 mmol) was added, and the reaction was stirred at room temperature for 3 hours. Saturated aqueous NaHCO3 solution was added for neutralization, and the mixture was extracted with EtOAc. The organic phase was then washed with saturated aqueous NaCl solution, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was separated by column chromatography to give 4-(4-aminopyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (0.60 g, yield: 69.6%).
[0352] 2. Preparation of Example Compounds
[0353] Example A1: (S)-1 1 ,5-dimethyl-4 3 -(prop-1-yn-1-yl)-1 1 H,4 1Preparation of H-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5 ...
[0354] Step 1: Synthesis of (S)-4-(4-((1-(4-((tert-butyldimethylsilyl)oxy)but-2-yl)-3-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one
[0355] (S)-1-(4-((tert-butyldimethylsilyl)oxy)but-2-yl)-6-chloro-3-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridine (353 mg, 0.93 mmol) and 4-(4-aminopyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (300 mg, 0.93 mmol) were dissolved in 1,4-dioxane (10 mL). Cs2CO3 (608 mg, 1.86 mmol) and XantPhos Pd-G3 (169 mg, 0.19 mmol) were then added. Under nitrogen, the mixture was heated at 120°C with stirring overnight. After completion of the reaction, the mixture was cooled to room temperature. Ethyl acetate was added for dilution, followed by washing with saturated brine and drying over anhydrous sodium sulfate. The filtrate was filtered, concentrated, and then separated by column chromatography to give (S)-4-(4-((1-(4-((tert-butyldimethylsilyl)oxy)but-2-yl)-3-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (0.32 g, yield: 51%). MS m / z (ESI): 663.4 [M+H] + .
[0356] Step 2: Synthesis of (S)-4-(4-((1-(4-hydroxybutan-2-yl)-3-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1,2-dihydro-3H-pyrazol-3-one
[0357] (S)-4-(4-((1-(4-((tert-butyldimethylsilyl)oxy)but-2-yl)-3-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (320 mg, 0.48 mmol) was dissolved in THF (5 mL), and then 1 M TBAF / THF solution (2.9 mL, 2.90 mmol) was added. Under nitrogen protection, the mixture was heated at 70°C with stirring for 2 hours. After the reaction, the mixture was cooled to room temperature and concentrated. The residue was separated by column chromatography to give (S)-4-(4-((1-(4-hydroxybutan-2-yl)-3-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1,2-dihydro-3H-pyrazol-3-one (98 mg, yield: 48%). MS m / z (ESI): 419.2 [M+H] + .
[0358] Step 3: (S)-1 1 ,5-dimethyl-4 3 -(prop-1-yn-1-yl)-1 1 H,4 1 Synthesis of H-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5 ...
[0359] (S)-4-(4-((1-(4-hydroxybutan-2-yl)-3-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1,2-dihydro-3H-pyrazol-3-one (98 mg, 0.23 mmol) was dissolved in toluene (5 mL), and CMBP (339 mg, 1.41 mmol) was added. Under nitrogen protection, the mixture was heated at 130°C for 24 hours. After the reaction was completed, the mixture was cooled to room temperature, diluted with CH2Cl2, and then washed with saturated NaHCO3 aqueous solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was separated by column chromatography to obtain (S)-1 1 ,5-dimethyl-4 3 -(prop-1-yn-1-yl)-1 1 H,4 1 H-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridine-2(2,4)-pyrimidine-1(4,5 ... + .
[0360] 1 HNMR (400MHz, DMSO-d6) δ10.33(s,1H),9.09(d,J=1.1Hz,1H),8.75(d,J=1.0Hz,1H),8.31(d,J=5.8Hz,1H),7.93(s,1H),6.74(d,J=5.8Hz,1H), 5.14(dd,J=10.4,6.8Hz,1H),4.37(t,J=11.4Hz,1H),4.01–3.87(m,1H) ,3.76(s,3H),2.17(s,3H),1.99(t,J=7.6Hz,1H),1.75(d,J=6.8Hz,3H).
[0361] Examples A2 to A3 can be prepared by selecting corresponding raw materials according to the synthesis method of Example A1:
[0362] Example 1: Preparation of 1'-methyl-3'-((1-methylpiperidin-4-yl)ethynyl)spiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)
[0363] Step 1: Synthesis of 4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one
[0364] (1-((6-Chloro-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol (245 mg, 0.633 mmol) was dissolved in 1,4-dioxane (15 mL), and then 4-(4-aminopyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (224 mg, 0.697 mmol), Cs2CO3 (413 mg, 1.266 mmol) and Brettphos-Pd-G3 (115 mg, 0.127 mmol) were added. Under nitrogen protection, the mixture was heated to 105°C and stirred overnight. After the reaction was complete, the mixture was cooled to room temperature, concentrated, and separated by column chromatography to give 4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (210 mg, 0.219 mmol, yield: 34.55%). MS m / z (ESI): 672.6 [M+H] + .
[0365] Step 2: Synthesis of 4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1,2-dihydro-3H-pyrazol-3-one
[0366] 4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (210 mg, 0.219 mmol) was dissolved in THF (12 mL), and TBAF / THF solution (0.46 mL, 1 M, 0.459 mmol) was added, and the mixture was heated at 70°C with stirring for 1 hour. After the reaction was completed, the reaction solution was concentrated, and the crude product was slurried with methanol, filtered, and dried to obtain 4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1,2-dihydro-3H-pyrazol-3-one (65 mg, 0.120 mmol, yield: 54.9%). MS m / z (ESI): 542.4 [M+H]+ .
[0367] Step 3: Synthesis of 1'-methyl-3'-((1-methylpiperidin-4-yl)ethynyl)spiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclic succinyl)
[0368] 4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1,2-dihydro-3H-pyrazol-3-one (60 mg, 0.111 mmol) was dissolved in toluene (15 mL), followed by the addition of CMBP (214 mg, 0.886 mmol). Under nitrogen, the mixture was heated to 130°C and allowed to react overnight. After the reaction was complete, the mixture was cooled to room temperature, quenched by the addition of saturated aqueous sodium bicarbonate solution, and extracted twice with dichloromethane. The organic phase was concentrated and separated by column chromatography to obtain a crude product, which was then separated by preparative HPLC to yield 1'-methyl-3'-((1-methylpiperidin-4-yl)ethynyl)spiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate) (14 mg, 0.024 mmol, yield: 21.7%). MS m / z (ESI): 524.4 [M+H] + .
[0369] 1 H NMR (400MHz, DMSO-d6) δ10.51(s,1H),9.54(s,1H),8.74(s,1H),8.34(d,J=5.8Hz,1H),8.02(s,1H),6.80(d,J=5 .8Hz,1H),3.82(s,3H),2.77–2.60(m,4H),2.18(s,3H),2.15–2.08(m,3H),1.96–1.83(m,6H),1.75-1.67(m,4H).
[0370] Examples 2 to 12 can be prepared by selecting corresponding raw materials according to the synthesis method of Example 1 or A1:
[0371] Example 13: Preparation of (R)-2-(1-(1'-methylspiro[cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate]-3'-yl)pyrrolidin-3-yl)propan-2-ol
[0372] Step 1: Synthesis of (R)-2-(1-(6-chloro-1-((1-(hydroxymethyl)cyclopentyl)methyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrrolidin-3-yl)propan-2-ol
[0373] (R)-2-(Pyrrolidin-3-yl)propan-2-ol hydrochloride (0.31 g, 1.86 mmol) and (1-((3-bromo-6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol (0.40 g, 1.16 mmol) were dissolved in 1,4-dioxane (8 mL), followed by the addition of Cs2CO3 (1.13 g, 3.48 mmol), Pd2(dba)3 (0.16 g, 0.17 mmol), and Xantphos (0.20 g, 0.35 mmol). After nitrogen substitution, the mixture was microwave-heated at 80°C for 2 hours. After completion of the reaction, the mixture was diluted with ethyl acetate and washed once with water and once with saturated brine. The organic layer was separated, washed with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the resulting crude product was separated by column chromatography (eluent: CH2Cl2 / MeOH 0-5%) to give (R)-2-(1-(6-chloro-1-((1-(hydroxymethyl)cyclopentyl)methyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrrolidin-3-yl)propan-2-ol (0.28 g, purity: 72.4%, yield: 44.1%). MS m / z (ESI): 393.2 [M+H] + .
[0374] Step 2: Synthesis of (R)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(2-hydroxypropane-2-yl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one
[0375] (R)-2-(1-(6-chloro-1-((1-(hydroxymethyl)cyclopentyl)methyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrrolidin-3-yl)propan-2-ol (0.40 g, 0.74 mmol) and 4-(4-aminopyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (0.24 g, 0.74 mmol) were dissolved in 1,4-dioxane (8 mL), and then Cs2CO3 (0.48 g, 1.47 mmol) and Brettphos-Pd-G3 (0.13 g, 0.15 mmol) were added. After nitrogen replacement, the mixture was heated in a microwave at 130°C for 2 hours. The reaction mixture was cooled and diluted with ethyl acetate, washed once with water and once with saturated brine. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (eluent: CH2Cl2 / MeOH 0-6%) to give (R)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(2-hydroxypropan-2-yl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (0.38 g, purity: 62.6%, yield: 47.6%). MS m / z (ESI): 678.6 [M+H] + .
[0376] Step 3: Synthesis of (R)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(2-hydroxypropan-2-yl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-1-methyl-1H-pyrazol-5-ol
[0377] (R)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(2-hydroxypropan-2-yl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (370 mg, purity: 62.6%, 0.35 mmol) was dissolved in THF (5.0 mL), and TBAF / THF solution (2.11 mL, 1.0 M, 2.11 mmol) was added, and the mixture was heated at 70°C for 1 hour. After the reaction was complete, the mixture was cooled to room temperature, concentrated, and separated by column chromatography to give (R)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(2-hydroxypropan-2-yl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-1-methyl-1H-pyrazol-5-ol (200 mg, purity: 85.4%, yield: 89.9%). MS m / z (ESI): 548.4 [M+H] + .
[0378] Step 4: Synthesis of (R)-2-(1-(1'-methylspiro[cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate]-3'-yl)pyrrolidin-3-yl)propan-2-ol
[0379] (R)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(2-hydroxypropane-2-yl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-1-methyl-1H-pyrazol-5-ol (180 mg, purity: 85.4%, 0.28 mmol) was dissolved in toluene (5 mL), and CMBP (542 mg, 2.25 mmol) was added. The mixture was heated at 130°C for 24 hours. After the reaction was complete, the mixture was cooled to room temperature and quenched by the addition of saturated aqueous NaHCO3 solution. The mixture was extracted twice with ethyl acetate, and the organic layers were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated, and separated by column chromatography (eluent: CH2Cl2 / MeOH 0-5%) to give (R)-2-(1-(1'-methylspiro[cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinyl)-3'-yl)pyrrolidin-3-yl)propan-2-ol (34.4 mg, yield: 22.9%). MS m / z (ESI): 530.4 [M+H] + .
[0380] 1 HNMR(400MHz,DMSO-d6)δ10.26(s,1H),9.18(s,1H),8.71(s,1H),8.29(d,J=5.8Hz,1H),8.00(s,1H),6.77(d,J=5.9Hz,1H),4.37(s,1H), 3.80(s,3H),3.71–3.61(m,1H),3.60–3.38(m,3H),2.41–2.28(m,1H),1.92(q,J=9.4Hz,4H),1.70(brs,2H),1.17(brs,3H),1.15(s,3H).
[0381] Example 14: Preparation of (S)-1'-methyl-3'-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)spiro[cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate]
[0382] Step 1: Synthesis of (S)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one
[0383] (S)-(1-((6-chloro-3-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)cyclopentyl)methanol (0.48 g, 0.98 mmol) and 4-(4-aminopyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (330 mg, 1.03 mmol) were dissolved in 1,4-dioxane (8 mL). Cs2CO3 (0.64 g, 1.95 mmol) and Brettphos-Pd-G3 (0.18 g, 0.195 mmol) were then added. After nitrogen substitution, the mixture was heated in a microwave oven at 130°C for 2 hours. The reaction solution was cooled, diluted with ethyl acetate, and then washed once with water and then with saturated brine. The organic layer was separated and dried over anhydrous sodium sulfate. Filtered and concentrated, and the resulting crude product was separated by column chromatography to give (S)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (0.32 g, purity: 73.6%, yield: 31.5%). MS m / z (ESI): 766.4 [M+H] + .
[0384] Step 2: Synthesis of (S)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1,2-dihydro-3H-pyrazol-3-one
[0385] (S)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (320 mg, purity: 73.6%, 0.31 mmol) was dissolved in ethanol (5.0 mL), and concentrated hydrochloric acid (0.50 mL, 12 M, 6.00 mmol) was added. The mixture was heated to 70°C for 2 hours. After the reaction was complete, the mixture was cooled to room temperature. The reaction mixture was concentrated and separated by column chromatography (eluent: CH2Cl2 / MeOH 0-5%) to give (S)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1,2-dihydro-3H-pyrazol-3-one (150 mg, purity: 86.8%, yield: 65.1%). MS m / z (ESI): 636.4 [M+H] + .
[0386] Step 3: Synthesis of (S)-1'-methyl-3'-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)spiro[cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate]
[0387] (S)-4-(4-((1-((1-(hydroxymethyl)cyclopentyl)methyl)-3-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-2-yl)-2-methyl-1,2-dihydro-3H-pyrazol-3-one (150 mg, purity: 86.8%, 0.21 mmol) was dissolved in dry toluene (20 mL), and CMBP (400 mg, 1.64 mmol) was added. The mixture was heated to 130°C and reacted for 24 hours. After the reaction was complete, the mixture was cooled to room temperature, quenched by the addition of saturated aqueous NaHCO₃, and extracted twice with ethyl acetate. The organic phases were combined, washed sequentially with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the resulting crude product was separated by preparative HPLC to give (S)-1'-methyl-3'-(3-(((trifluoromethyl)sulfonyl)methyl)pyrrolidin-1-yl)spiro[cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate] (26.8 mg, yield: 20.7%). MS m / z (ESI): 618.4 [M+H] + .
[0388] 1 HNMR(400MHz,DMSO-d6)δ10.28(s,1H),9.21(s,1H),8.69(s,1H),8.30(d,J =5.8Hz,1H),8.00(s,1H),6.76(d,J=5.9Hz,1H),4.60(brs,2H),4.11(d,J=6 .7Hz,2H),3.89–3.69(m,5H),3.61(q,J=8.3Hz,1H),3.38(t,J=9.0Hz,1H), 2.90(p,J=7.6Hz,1H),2.33–2.29(m,1H),2.05–1.84(m,4H),1.70(brs,2H).
[0389] Examples 15 to 47 and Example A4 were prepared by selecting corresponding raw materials with reference to the route of Example A1, 1, 13 or 14.
[0390] Example 48: Preparation of (R)-N-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-yl)methanesulfonamide
[0391] Step 1: Synthesis of (R)-1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-amine
[0392] Tert-butyl (R)-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-yl)carbamate (prepared with reference to Example 1) (70 mg, purity: 77.1%, 0.10 mmol) was dissolved in CH2Cl2 (3.0 mL), cooled in an ice-water bath, and HCl / dioxane solution (0.46 mL, 4.0 M, 1.84 mmol) was added, and the reaction was allowed to react at room temperature for 1 hour. The reaction was complete and concentrated to give (R)-1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-amine, which was used directly in the next reaction. MS m / z(ESI):487.3[M+H] + .
[0393] Step 2: Synthesis of (R)-N-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-yl)methanesulfonamide
[0394] The crude product obtained in the previous step was dissolved in dry CH2Cl2 (3.0 mL). Triethylamine (0.10 mL, 0.74 mmol) and methanesulfonic anhydride (32 mg, 0.18 mmol) were added under ice-water cooling and allowed to react at room temperature for 1 hour. The reaction was quenched by adding saturated aqueous NaHCO3 solution, followed by extraction twice with CH2Cl2. The organic phases were combined, washed sequentially with saturated brine, and dried over anhydrous sodium sulfate. Filtered, concentrated, and separated by column chromatography to afford (R)-N-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinyl)-3'-yl)pyrrolidin-3-yl)methanesulfonamide (7.3 mg, yield: 13%). MS m / z (ESI): 565.3 [M+H] + .
[0395] 1 H NMR (400MHz, DMSO-d6) δ10.26(s,1H),9.21(s,1H),8.71(d,J=0.9Hz,1H),8.30(d,J =5.8Hz,1H),8.00(s,1H),6.77(dd,J=5.8,1.3Hz,1H),4.61(brs,2H),4.08(p,J=6. 3Hz, 1H), 3.80 (s, 4H), 3.68 (dd, J=8.7, 5.9Hz, 1H), 3.58 (q, J=7.8Hz, 1H), 3.41 (dd, J=9.9,5.5Hz,1H),3.00(s,3H),2.35–2.24(m,2H),2.04–1.85(m,4H),1.70(s,2H).
[0396] Example 49: Preparation of (R)-N-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-yl)acetamide
[0397] (R)-1-(1'-Methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinyl)-3'-yl)pyrrolidin-3-amine (0.010 mmol) was dissolved in CH2Cl2 (3.0 mL). Triethylamine (0.10 mL, 0.74 mmol) was added under ice-water cooling, followed by the slow dropwise addition of acetyl chloride (0.03 mL, 0.46 mmol). The reaction was maintained at 0°C for 1 hour. After completion of the reaction, saturated aqueous NaHCO3 was added to quench the reaction. The mixture was extracted twice with CH2Cl2. The organic phases were combined, washed sequentially with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated, and separated by column chromatography to give (R)-N-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-yl)acetamide (14.1 mg, yield: 26%). MS m / z (ESI): 529.4 [M+H] + .
[0398] 1 HNMR (400MHz, DMSO-d6) δ10.26(s,1H),9.21(d,J=1.0Hz,1H),8.71(d,J=1.0Hz,1H),8.30(d,J= 5.8Hz,1H),8.18(d,J=6.7Hz,1H),8.00(s,1H),6.76(dd,J=5.8,1.5Hz,1H),4.65(brs,2H),4.37 (q,J=5.8Hz,1H),3.80(s,3H),3.75(dd,J=10.0,6.5Hz,1H),3.67(q,J=5.6Hz,1H),3.59(q,J=8. 1Hz, 1H), 3.37–3.35 (m, 1H), 2.20 (q, J = 6.1Hz, 2H), 1.94–1.87 (m, 3H), 1.82 (s, 3H), 1.70 (s, 2H).
[0399] Example 50: Preparation of (R)-2,2,2-trifluoro-N-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-yl)acetamide
[0400] Step 1: Synthesis of (R)-1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-amine
[0401] Tert-butyl (R)-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-yl)carbamate (50 mg, 0.08 mmol) was dissolved in CH2Cl2 (3.0 mL) and cooled in an ice-water bath. CF3COOH (0.24 mL, 3.28 mmol) was added and stirred for 1 hour. The mixture was then allowed to warm to room temperature and allowed to react for 3 hours. The solvent was removed by concentration to obtain the crude product, which was used directly in the next step. MS m / z (ESI): 487.2 [M+H] + .
[0402] Step 2: Synthesis of (R)-2,2,2-trifluoro-N-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-yl)acetamide
[0403] (R)-1-(1'-Methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinyl)-3'-yl)pyrrolidin-3-amine (0.08 mmol) was dissolved in CH2Cl2 (3.0 mL). Triethylamine (0.03 mL, 0.25 mmol) was added under ice-water cooling, followed by slow dropwise addition of TFAA (0.02 mL, 0.12 mmol). The reaction was maintained at 0°C for 1 hour. After completion of the reaction, saturated aqueous NaHCO3 solution was added to quench the reaction. The mixture was extracted twice with CH2Cl2. The organic phases were combined, washed sequentially with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated, and separated by column chromatography to give (R)-2,2,2-trifluoro-N-(1-(1'-methylspiro(cyclopentane-1,6'-8-oxa-3-aza-4(6,1)-pyrazolo[4,3-c]pyridin-2(2,4)-pyrimidin-1(4,5)-pyrazoloheterocyclosuccinate)-3'-yl)pyrrolidin-3-yl)acetamide (13.3 mg, yield: 27%). MS m / z (ESI): 583.4 [M+H] + .
[0404] 1 H NMR (400MHz, DMSO-d6) δ10.29(s,1H),9.75(d,J=6.8Hz,1H),9.22(s,1H),8.74(s,1H),8.30(d,J=5.8Hz,1H),8.00(s,1H),6.76(dd,J=5.9,1.5Hz,1H), 4.65(brs,2H),4.51(s,1H),3.87–3.81(m,1H),3.80(s,3H),3.77–3.67(m,1H),3.61(d,J=7.6Hz,1H),3 .53(dd,J=10.2,4.6Hz,1H),2.37–2.23(m,2H),2.05(dq,J=13.0,6.6Hz,2H),1.91(s,3H),1.70(s,2H).
[0405] Examples 51 to 58 can be prepared by referring to the synthesis method of Example 48, 49 or 50 and selecting the corresponding raw materials.
[0406] The NMR data of the compound prepared in the above example are as follows:
[0407] 3. Biological Test Evaluation
[0408] (Cell proliferation assay)
[0409] (1) Reagents and consumables
[0410] DMEM medium (Gibco, Cat#11965118)
[0411] RPMI1640 culture medium (Gibco, Cat#11875119)
[0412] Fetal bovine serum (FBS) (GBICO, Cat#10099-141)
[0413] Luminescent cell viability assay kit (Promega, Cat#G7572)
[0414] Black transparent flat bottom 96-well plate ( Cat#3603)
[0415] (2) Instruments
[0416] SpectraMax Multilabel Microplate Reader MD, 2104-0010A;
[0417] CO2 incubator, Thermo Scientific 3100 series;
[0418] Biological safety cabinet, Thermo Scientific, 1300 series model A2;
[0419] Inverted microscope, Olympus, CKX41SF;
[0420] Siemens refrigerator, KK25E76TI.
[0421] (III) Cell lines and culture conditions
[0422] (IV) Experimental steps
[0423] 1. Cell culture and inoculation:
[0424] (1) Harvest cells in the logarithmic growth phase and count the cells using a platelet counter. Detect cell viability by trypan blue exclusion to ensure that the cell viability is above 90%.
[0425] (2) Adjust the cell concentration to achieve the desired final density; add 90 μL of cell suspension to a 96-well plate.
[0426] (3) The cells were incubated in a 96-well plate at 37°C, 5% CO2 and 95% humidity overnight.
[0427] 2. T0 benchmark data:
[0428] (1) Add 10 μL of PBS to each well of the T0 plate containing cells.
[0429] (2) Thaw the CTG reagent and equilibrate the cell plate to room temperature for 30 minutes.
[0430] (3) Add an equal volume of CTG solution to each well.
[0431] (4) Shake on an orbital shaker for 5 minutes to lyse the cells.
[0432] (5) Place the cell plate at room temperature for 20 minutes to stabilize the luminescence signal.
[0433] (6) Read the T0 fluorescence signal value.
[0434] 3. Compound dilution and addition
[0435] (1) According to the compound information table, add the corresponding volume of DMSO to the corresponding compound powder to prepare a 10 mM stock solution.
[0436] (2) Prepare 1000-fold and 3.16-fold diluted compound solutions.
[0437] (3) The 1000× diluted compound solution was diluted 100-fold with PBS to prepare a 10-fold compound solution. The highest concentration was 10 μM. Nine concentrations were diluted 3.16-fold. 10 μL of the drug solution was added to each well of a 96-well plate and the cells were inoculated. Three replicate wells were set for each compound concentration. The final DMSO concentration was 0.1%.
[0438] (4) The cells were placed in a 96-well plate containing drugs at 37°C, 5% CO2 and 95% humidity for 72 hours before CTG analysis.
[0439] 4. Fluorescence signal reading
[0440] (1) Thaw CTG reagent and equilibrate the cell plate to room temperature for 30 minutes.
[0441] (2) Add an equal volume of CTG solution to each well.
[0442] (3) Shake on an orbital shaker for 5 minutes to lyse the cells.
[0443] (4) Place the cell plate at room temperature for 20 minutes to stabilize the fluorescent signal.
[0444] (5) Read the fluorescence value.
[0445] 5. Data processing
[0446] The data were analyzed using GraphPad Prism 7.0 software, and nonlinear S-curve regression was used to fit the data to obtain the dose-effect curves, from which the IC was calculated. 50 Value (unit: nM), specific experimental results are shown in Table 1:
[0447] Cell viability (%) = (Lum test drug - Lum culture medium control) / (Lum cell control - Lum culture medium control) × 100%.
[0448] Table 1: Biological test results
[0449] The “positive compound” used in the biological test evaluation and mouse pharmacokinetic experiments of this application is one of the compounds with the best activity range in WO2021168074A1 (Compound 101), and its chemical structure is as follows:
[0450] Judging from the biological activity data of the compounds in the specific examples, the series of compounds of the present invention have a strong inhibitory effect on various EGFR-resistant C797S mutations at the cellular level, including EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation and Del19 / T790M / C797S triple mutation, and have high selectivity for EGFR WT.
[0451] 4. Pharmacokinetic Experiments in Mice
[0452] (1) Research objectives
[0453] The purpose of this study is to study the pharmacokinetic behavior of some compounds of the present invention. The administration method is: single oral administration (PO) to ICR mice.
[0454] (2) Experimental plan
[0455] 1. Experimental drugs
[0456] The compounds used in this test are from the specific examples of the present invention and the listed positive compounds.
[0457] 2. Experimental Animals
[0458] ICR mice male N=9 Original source: Shanghai Xipul-Bikai Laboratory Animal Co., Ltd.
[0459] 3. Drug preparation and administration
[0460] Weigh the compounds and dissolve them in the corresponding solvent (10% PG + 10% 80% pH 3 citrate buffer, shaken and sonicated to prepare a 1 mg / mL solution. Nine mice were fasted overnight and orally administered at a dose of 10 mg / kg (or IV 2 mg / kg).
[0461] 4. Sample collection
[0462] Approximately 90 μL of blood was collected from the submandibular vein at each time point, anticoagulated with sodium heparin, placed on ice, and centrifuged within 1 hour to separate plasma (centrifugation conditions: 8000 rpm, 6 minutes, 2-8°C). Blood was collected at 0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours. Samples were stored at -20°C.
[0463] For each 40 μL plasma sample, add 160 μL of ice-cold acetonitrile containing an internal standard, vortex for 3 minutes, and centrifuge at 11,000 rpm for 5 minutes. 100 μL of the supernatant is added to 100 μL of water, and 5 μL is injected into the LC / MS / MS for analysis.
[0464] 5. Test results
[0465] Table 2: Pharmacokinetic experimental results
[0466] Based on the pharmacokinetic data of the compounds in the above specific examples, the compounds of this invention exhibit excellent pK values after a single oral dose (10 mg / kg) in mice. Compared to the positive compounds, the AUC of the compounds of this invention is at least fivefold higher, and some of the compounds in the examples show an AUC increase of several dozen-fold. Experiments demonstrate that the compounds of this invention significantly enhance oral exposure and exhibit excellent oral bioavailability, potentially resolving the issue of the poor pK values of positive compounds, which make them unsuitable for oral administration.
[0467] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above disclosure, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: in, X1 for CR a or N; X2 is CR b or N; X3 for CR c or N; X4 for CR d or N; L1 is CR 5a R 5b ; L2 is (CR 5c R 5d ) p , NR 6a , O, S, S(O), S(O)2 or C(O); L3 is key, CR 5e R 5f NR 6b , O, S, S(O), S(O)2 or C(O); Alternatively, L2 and L3 together form C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; L4 is CR 5g R 5h 、O、S、S(O)、S(O)2、NR 6c or C(O); Ring A is C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; R1 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 alkyl Base-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 3-12 Cycloalkyl substituted C 1-10 Alkyl, 3-12 membered heterocyclic substituted C 1-10 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Each R2 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 Substituents replaced by; Each R3, R a and R b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 ; R4 and R c are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 ; R d Selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 ; R 5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 , or, R 5a and R 5b Together with the carbon atom directly connected to it, it forms a C(O), C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 Heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Each R 5c and R 5d are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 , or, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted with a substituent, provided that when R 5c or R 5d H or C 1-4 When alkyl, R1 is an optionally substituted C 2-10 Alkynyl, or L3 is O, S, S(O) or S(O)2; R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 , or, R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; R 5g and R 5h are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 , or, R 5g and R 5h Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=N-R7)R8, -C 0-8 Alkyl-N=S(O)R8R9, -C 0-8 Alkyl-N=SR8R9, -C 0-8 Alkyl-OS(O)2R 10 、-C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)SR 11 、-C 0-8 Alkyl-SC(O)R 12 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-P(O)(R 12 )2. -C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 and -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; R 6a Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 11 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 13 R 14 substituted by a substituent; R 6b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 11 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 13 R 14 substituted by a substituent; R 6c Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 11 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 13 R 14 substituted by a substituent; Each R7 is independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)R 12 or -C 0-8 Alkyl-C(O)NR 13 R 14 The above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 or -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Each R8 and R9 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, or, R8 and R9 together with the sulfur atom to which they are directly connected form a 3-10 membered heterocyclic group, the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 10 、-C 0-8 Alkyl-OR 11 、-C 0-8 Alkyl-C(O)OR 11 、-C 0-8 Alkyl-C(O)R 12 、-C 0-8 Alkyl-OC(O)R 12 、-C 0-8 Alkyl-NR 13 R 14 、-C 0-8 Alkyl-C(=NR 13 )R 12 、-C 0-8 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-8 Alkyl-C(O)NR 13 R 14 or -C 0-8 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Each R 10 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 13 R 14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent; Each R 11 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent; Each R 12 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 13 R 14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent; Each R 13 and R 14 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl Acyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent; Or, R 13 and R 14 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, methylsulfonylmethyl, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent; m is 0, 1, 2, 3 or 4; n is 0, 1, or 2; p is 1 or 2; and Each r is independently 0, 1 or 2.
2. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: X1 for CR a or N; X2 is CR b or N; X3 for CR c or N; X4 for CR d or N; L1 is CR 5a R 5b ; L2 is (CR 5c R 5d ) p , NR 6a , O, S, S(O), S(O)2 or C(O); L3 is key, CR 5e R 5f NR 6b , O, S, S(O), S(O)2 or C(O); Alternatively, L2 and L3 together form C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; L4 is CR 5g R 5h 、O、S、S(O)、S(O)2、NR 6c or C(O); Ring A is C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl; R1 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Each R2 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、 -C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Each R3, R a and R b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 ; R4 and R c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 ; R d Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 ; R 5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 , or, R 5a and R 5b Together with the carbon atom directly connected to it, it forms a C(O), C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 aryl or 5-8 membered heteroaryl, each of the above groups being independently optionally further substituted with one or more selected from deuterium, Halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Each R 5c and R 5d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 , or, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted with a substituent, provided that when R 5c or R 5d H or C 1-4 When alkyl, R1 is an optionally substituted C 2-10 Alkynyl, or L3 is O, S, S(O) or S(O)2; R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 , or, R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; R 5g and R 5h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 , or, R 5g and R 5h Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Among them, R 6a 、R 6b 、R 6c 、R7、R8、R9、R 10 、R 11 、R 12 、R 13 、R 14 , m, n, p and r as described in claim 1.
3. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R7 is independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)R 12 or -C 0-4 Alkyl-C(O)NR 13 R 14 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 or -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Each R8 and R9 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 aryl or 5-8 membered heteroaryl, or, R8 and R9 together with the sulfur atom to which they are directly connected form a 3-6 membered heterocyclic group, the above groups are optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 or -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; Each R 10 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 13 R 14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent; Each R 11 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent; Each R 12 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 13 R 14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 13 R 14 substituted by a substituent; Each R 13 and R 14 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Or, R 13 and R 14 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-6 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, methylsulfonylmethyl, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; and Each r is independently 0, 1 or 2.
4. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is the compound of formula (II): in, X1 for CR a or N; X2 is CR b or N; X3 for CR c or N; X4 for CR d or N; L1 is CR 5a R 5b ; L2 is (CR 5c R 5d ) p , NR 6a , O, S, S(O), S(O)2 or C(O); L3 is key, CR 5e R 5f or C(O); L4 is CR 5g R 5h 、O、S、S(O)、S(O)2、NR 6c or C(O); R1 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 alkyl Base, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; R 2a Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-C(O)R 12 and -C(O)NR 13 R 14 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; R 2b Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; R 3a 、R 3b 、R a and R b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 ; R4 and R c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、 -P(O)(R 12 )2, -NR 13 R 14 , -C(=NR 13 )R 12 , -N(R 13 )-C(=NR 14 )R 12 , -C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 ; R d Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 ; R 5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 , or, R 5a and R 5b Together with the carbon atom directly connected to it, it forms a C(O), C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; Each R 5c and R 5d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 , or, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted with a substituent, provided that when R 5c or R 5d H or C 1-4 When alkyl, R1 is an optionally substituted C 2-10 Alkynyl; R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、 -N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 , or, R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; R 5g and R 5h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 , or, R 5g and R 5h Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; Among them, R 6a 、R 6c 、R7、R8、R9、R 10 、R 11 、R 12 、R 13 、R 14 , p and r as described in claim 1.
5. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is the compound of formula (III): in, X1 for CR a or N; X2 is CR b or N; X3 for CR c or N; X4 for CR d or N; L1 is CR 5a R 5b ; L2 is (CR 5c R 5d ) p ; L3 is key, CR 5e R 5f or C(O); L4 is CR 5g R 5h 、O、NR 6c or C(O); R1 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=N-R7)R8, -C 0-4 Alkyl-N=S(O)R8R9, -C 0-4 Alkyl-N=SR8R9, -C 0-4 Alkyl-N(R 13 )-S(O)2R 10 、-C 0-4 Alkyl-OS(O)2R 10 、-C 0-4 Alkyl-S(O) r R 10 、-C 0-4 Alkyl-OR 11 、-C 0-4 Alkyl-C(O)OR 11 、-C 0-4 Alkyl-C(O)SR 11 、-C 0-4 Alkyl-SC(O)R 12 、-C 0-4 Alkyl-C(O)R 12 、-C 0-4 Alkyl-OC(O)R 12 、-C 0-4 Alkyl-P(O)(R 12 )2. -C 0-4 Alkyl-NR 13 R 14 、-C 0-4 Alkyl-C(=NR 13 )R 12 、-C 0-4 Alkyl-N(R 13 )-C(=NR 14 )R 12 、-C 0-4 Alkyl-C(O)NR 13 R 14 and -C 0-4 Alkyl-N(R 13 )-C(O)R 12 substituted by a substituent; R 2a Selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; R 2b Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 alkyl Base, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; R 3a 、R 3b 、R a and R b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5; R c Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5; R d Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5; R 5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5, or R 5a and R 5b Together with the carbon atom directly connected to it, it forms a C(O), C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; When p is 1, R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, each of the above groups is independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 Substituents substituted by Or, when p is 2, one of the sets R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, when one group R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 When the cycloalkyl group or the 4-6 membered heterocyclic group, the other group R 5c and R 5d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 ; R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5, or R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; R 5g and R 5h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5, or R 5g and R 5h Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; R 6c Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 11 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 13 R 14 substituted by a substituent; Among them, R7, R8, R9, R 10 、R 11 、R 12 、R 13 、R 14 , p and r as described in claim 1.
6. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is the compound of formula (IV): in, L1 is CR 5a R 5b ; L2 is CR 5c R 5d ; L3 is CR 5e R 5f ; L4 is O; R1 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -SF5, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R7)R8, -N=S(O)R8R9, -N=SR8R9, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)SR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-P(O)(R 12 )2、-NR 13 R 14 、-C(=NR 13 )R 12 、-N(R 13 )-C(=NR 14 )R 12 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; R 2a Selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5; R 2b Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -SF5, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5; R 5a and R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R 5a and R 5b Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic ring, each of the above groups is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5; R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, each of the above groups is independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5; R 5e and R 5f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R 5e and R 5f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 The above groups are each independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5; Among them, R7, R8, R9, R 10 、R 11 、R 12 、R 13 、R 14 and r as claimed in claim 1.
7. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: L1 is CR 5a R 5b ; L2 is CR 5c R 5d ; L3 is CR 5e R 5f ; L4 is O; R 5a and R 5b each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl, each of which is optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5; R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5; and R 5e and R 5f Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano group, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl, and the above groups are each independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano group, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5.
8. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 2a is selected from hydrogen, deuterium, hydroxy, methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5; and R 2b Selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl and -SF5, each of the above groups being independently further substituted by one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, =O, =S and -SF5.
9. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is the compound of formula (V): in, R1 is selected from C 2-4 Alkenyl, C 2-4 Alkynyl and 3-8 membered heterocyclic groups, each of which is independently optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, =O, =S, -SF5, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-SC(O)R 12 、-C(O)R 12 、-OC(O)R 12 、-NR 13 R 14 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 The above groups are each independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-C(O)OR 11 、-C(O)R 12 、-OC(O)R 12 、-NR 13 R 14 、-C(O)NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; R 2a Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 substituted by a cycloalkyl group or a 3-6 membered heterocyclic group; R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, each of the above groups is independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Substituted by cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF5; Among them, R 10 、R 11 、R 12 、R 13 、R 14 and r as claimed in claim 1.
10. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group.
11. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 5c and R 5d Together with the carbon atom to which it is directly attached, it forms a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxolanyl or oxhexyl group.
12. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is C 2-4 Alkynyl, the C 2-4 Alkynyl is optionally further substituted with one or more radicals selected from deuterium, C 1-4 Alkyl, C 3-6 The substituents of cycloalkyl and 3-6 membered heterocyclic groups are substituted, each of the above groups being independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 The alkyl group is substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic group.
13. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is ethynyl, which is optionally further substituted with one or more substituents selected from the group consisting of deuterium, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azetyl, each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azetyl.
14. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is ethynyl, which is optionally further substituted by one or more substituents selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azetyl, each of which is independently optionally further substituted by one or more substituents selected from deuterium, fluorine, bromine, cyano, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl and trideuteriomethyl.
15. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is R 1a is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl and trideuteriomethyl; R 1b Selected from hydrogen, methyl, ethyl, propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, Deuterium, dideuterium and trideuterium.
16. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is a 4-8 membered nitrogen-containing heterocyclic group, wherein the 4-8 membered nitrogen-containing heterocyclic group is optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, =O, -N(R 13 )-S(O)2R 10 、-S(O) r R 10 、-OR 11 、-OC(O)R 12 、-NR 13 R 14 and -N(R 13 )-C(O)R 12 Substituents substituted, the C 1-4 The alkyl group is optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -N(R 13 )-S(O)2R 10 、-OS(O)2R 10 、-S(O) r R 10 、-OR 11 、-OC(O)R 12 、-NR 13 R 14 and -N(R 13 )-C(O)R 12 substituted by a substituent; Among them, R 10 、R 11 、R 12 、R 13 、R 14 and r as described in claim 9.
17. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is the following structure: R 1c Selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the C 1-4 The alkyl group is optionally further substituted with one or more radicals selected from deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -S(O) r R 10b AND-OR 11a substituted by a substituent; R 1d Selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a ; R 1e Selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the C 1-4 The alkyl group is optionally further substituted with one or more radicals selected from deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -S(O) r R 10b AND-OR 11a substituted by a substituent; R 1f Selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the C 1-4 The alkyl group is optionally further substituted with one or more radicals selected from deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -S(O) r R 10b AND-OR 11a substituted by a substituent; Each R 10a are independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups; Each R 10b are independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, each of which is independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, C 1-4 Alkyl and C 1-4 substituted by an alkoxy substituent; Each R 11a are independently hydrogen or C 1-4 alkyl; Each R 12a are independently selected from hydrogen, C 1-4 Alkyl, C 1-4 Alkoxy and C 3-6 Cycloalkyl, each of the above groups independently being optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxyl and cyano; Each R 13a are each independently hydrogen or C 1-4 alkyl; and Each r is independently 0, 1 or 2.
18. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is the following structure: R 1c Selected from hydrogen, deuterium, fluorine, bromine, methyl, ethyl, propyl, isopropyl, butyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the methyl, ethyl, propyl, isopropyl or butyl group is independently optionally further substituted with one or more selected from deuterium, methyl, ethyl, propyl, isopropyl, butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, -S(O) r R 10b AND-OR 11a substituted by a substituent; R 1d is selected from the group consisting of hydrogen, deuterium, fluorine, bromine, methyl, ethyl, propyl, isopropyl and butyl; R 1e Selected from hydrogen, deuterium, fluorine, bromine, methyl, ethyl, propyl, isopropyl, butyl, -N(R 13a )-S(O)2R 10a 、-OR 11a and -N(R 13a )-C(O)R 12a , the methyl, ethyl, propyl, isopropyl or butyl group is independently optionally further substituted with one or more selected from deuterium, methyl, ethyl, propyl, isopropyl, butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, -S(O) r R 10b AND-OR 11a substituted by a substituent; Each R 10a independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl, and azohexyl; Each R 10b independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azohexyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy and propoxy; Each R 11a independently selected from hydrogen, methyl, ethyl, propyl, isopropyl and butyl; Each R 12a independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, propoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl and cyano; Each R 13a are each independently hydrogen; Each r is independently 0, 1 or 2.
19. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is the following structure: R 1g is hydrogen, deuterium or methyl; R 1h is hydrogen, deuterium or methyl; R 1j is hydrogen, deuterium or methyl; q is 0, 1 or 2; R 10a is selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azohexyl; R 10b selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl and azohexyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy and propoxy; Each R 11a independently selected from hydrogen, methyl, ethyl, propyl, isopropyl and butyl; R 12a is selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, propoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, each of which is independently further substituted by one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl and cyano.
20. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 2a Selected from hydrogen, deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 cycloalkyl and 3-6 membered heterocyclic groups.
21. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 2a is selected from hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl.
22. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Selected from the following compounds:
23. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 22, a stereoisomer thereof or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
24. Use of a compound of formula (I) according to any one of claims 1 to 22, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating and / or preventing tumors or metastatic diseases at least partially associated with EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation, and Del19 / T790M / C797S triple mutation.
25. The use according to claim 24, characterized in that The tumor or metastatic disease is a tumor and / or metastatic disease caused by excessive proliferation and induction of cell death disorder.
26. The use according to claim 24, characterized in that The tumor or metastatic disease is selected from lung cancer, colon cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, uterine cancer, gastric cancer, non-small cell lung cancer, leukemia, myelodysplastic syndrome, malignant lymphoma, head and neck tumors, thoracic tumors, gastrointestinal tumors, endocrine tumors, breast and other gynecological tumors, urological tumors, skin tumors, sarcomas, inverted papilloma of the nasal cavity and paranasal sinuses, or squamous cell carcinoma of the nasal cavity and paranasal sinuses associated with inverted papilloma of the nasal cavity and paranasal sinuses.
27. A compound of formula (I) according to any one of claims 1 to 22, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for treating and / or preventing lung cancer, colon cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, uterine cancer, gastric cancer, non-small cell lung cancer, leukemia, myelodysplastic syndrome, malignant lymphoma, head and neck tumors, thoracic tumors, gastrointestinal tumors, endocrine tumors, breast and other gynecological tumors, urological tumors, skin tumors, sarcomas, sinonasal inverted papilloma, or sinonasal squamous cell carcinoma associated with at least part of EGFR L858R / C797S double mutation, EGFR Del19 / C797S double mutation, L858R / T790M / C797S triple mutation, and Del19 / T790M / C797S triple mutation.
